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ABSTRACT 
 
 
 Mouse Hemogen (Hemgn) is regarded as a homologue of human Erythroid 
Differentiation Associated Gene (EDAG). EDAG overexpression has been postulated for 
association with some leukemia cases. Meanwhile, Hemgn has been found to contribute 
to Hoxb4 mediated hematopoietic stem cell expansion. Based on these postulations and 
evidences, a Hemgn knockout mouse model has been generated to study its function in 
normal and stress hematopoiesis. 
 
I confirmed the Hemgn expression in hematopoietic organs including bone 
marrow and spleen, as well as round spematids in testis. Hemgn is expressed in mouse 
hematopoietic stem cells and erythroid progenitor cells. Moreover, Hemgn was also 
found in basophilic, polychromatic and orthochromatic erythroblast cells and 
megakaryocytes, but absent in mature red blood cells and other differentiated blood cells. 
 
Hemgn knockout animals showed normal steady-state and stress hematopoiesis 
and erythropoiesis. However, upon transplantation, a slight defect in lymphoid 
reconstitution was observed. 
 
By generating a deletion mutant of the predicted nuclear localization signal, I 
conclude the amino acids 61 to 78 is a functional nuclear localization signal. Both the 
nuclear localization signal and the predicted coiled-coil domain were required for Hemgn 
to protect Ba/F3 cells from IL-3 withdrawal induced apoptosis. However, the same anti-
apoptotic effect of Hemgn was not seen in the myeloid 32D cell line, indicating it may 
require specific cell context. 
 
In conclusion, Hemgn may be an anti-apoptotic protein and may be involved in 
lymphoid development. 
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CHAPTER 1.    INTRODUCTION 
 
 
 This chapter is a brief introduction on the background knowledge related to this 
study, including general concepts in hematopoiesis, erythropoiesis and gene targeting. 
More detailed and specific introduction is given in context of results in Chapter 4. 
 
 
Hematopoiesis and Hematopoietic Stem Cell 
 
 
The Old Wisdom and Modern History 
 
 Hematopoiesis literally refers to the formation of blood. The conjugation between 
hematopoietic system and stem cell biology is not incidental. Hematopoietic stem cell 
(HSC) is defined by the ability to reconstitute lethally irradiated hosts’ hematopoiesis, to 
self-renew, and to differentiate into all mature blood cell types. Specific hematopoietic 
cells can be sorted based on surface marker expression profile, and tested by 
transplantation to study the stem cell activity. The first mention of a stem cell in 
hematopoietic system could date back to 19
th
 century by Artur Pappenheim [1], who 
proposed a monophyletic pedigree of all blood cells [2] and was elaborated by Ernst 
Neumann and Alexander Maximow [3]. On the contrary was Paul Ehrlich of the 
polyphyletic school, who considered the precursors of lymphocytes and leukocytes were 
in different organs [2]. The initiation of the unitarian hematopoietic stem cell idea was 
early, but it was not until 1961 that this idea was experimentally verified by a spleen 
colony forming assay [4]. 
 
 Like other findings in medicine, the lack of knowledge of stem cells did not 
impede the empirical application of stem cell transplantation. The first unsuccessful 
attempt of human marrow transplant was in 1939 [5]. In 1950s, in dealing with people 
exposed to lethal dose of radiation during WWII, transplants from spleen and bone 
marrow were found to rescue survival [6]. The first sustained engraftment was achieved 
in 1965 for an acute lymphoblastic leukemia (ALL) patient who received marrow 
infusion from 6 related donors [5]. In 1968 after the discovery of human leukocyte 
antigen (HLA) system, children with severe combined immunodeficiency (SCID) and 
with Wiskott-Aldrich syndrome (WAS) were the first cases with successful marrow 
transplants [5]. In 1970s, more patients with acute leukemia or aplastic anemia underwent 
marrow transplantation from siblings [5], many of whom are still surviving. Successful 
cell transplant from unrelated donors were reported in 1977, followed by the first 
successful autologous hematopoietic cell transplant in 1978 [5]. By 2000, more than 
500000 patients had been transplanted since 1970s [5]. 
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Markers of HSC 
 
 HSCs, though a heterogeneous population, still share some common features 
between individual cells. Several combinations of markers can enrich highly purified 
HSCs. At this time, there is no “magical” combination of markers to exclusively separate 
HSCs from other cell types. 
 
 A commonly used marker combination is Lin
-
Sca1
+
c-Kit
+
 or LSK. Only a small 
fraction of LSK cells are true stem cells, approximately 1 out of 100. To further enrich, 
CD34 or Thy-1 is regularly added. The expression patterns of these two markers are 
different in humans and mice. HSC of rat and human expresses high level of Thy-1 [7], 
whereas its level is low in mouse HSC [8]. The relationship between CD34 expression 
and stem cell identity is dynamic in mouse. Under homeostatic conditions, CD34
-
LSK 
population represents stem cell activity. However during the reconstitution phase after 
transplantation, these cells become CD34
+
 without loss of stem cell activity, whereas they 
turn back to CD34
-
 once reconstitution phase is finished. Human is different from mouse 
in CD34 expression in HSC. Human HSC is always CD34
+
. A relatively new marker is 
CD150, which in combination with LSK and CD48 can separate highly enriched HSC 
population [9]. 
 
 Besides cell surface markers, HSCs exhibit a biological feature that renders them 
drug resistant. Stem cells are responsible for tissue regeneration throughout the whole life, 
so there is an intrinsic need for them to be resistant to various environmental insults such 
as chemicals and drugs. Stem cells meet this biological need by making pumps across 
cell membrane. Once the chemicals diffuse into a stem cell, they can be actively pumped 
out through ATP-binding cassette transporters [10]. Enabled by this feature, stem cells 
are resistant to DNA dyes like Hoechst-33342, thus can be sorted via flow cytometry as a 
population of low fluorescence in both blue and red spectrum. This is referred to as the 
“side population” [11]. 
 
 
Adult Hematopoiesis and Anatomy 
 
 Adult hematopoiesis is a series of hierarchical events (Figure 1-1). In adult, a 
long term hematopoietic stem cell (LT-HSC) first becomes a short term hematopoietic 
stem cell (ST-HSC), and then further turns into multipotent progenitor (MPP). The 
difference between LT-HSC, ST-HSC and MPP is their ability to self-renew. LT-HSC 
can self-renew for whole life time, whereas ST-HSC can only support self-renewal for 6 
to 8 weeks [12]. The self-renewal ability of MPP is very limited, and under transplant 
conditions it is difficult to detect [13], yet this population is undifferentiated [14]. This 
cascade is not reversible. MPP gives rise to lineage restricted progenitor cells, including 
common lymphoid progenitor (CLP) and common myeloid progenitor (CMP) in the bone 
marrow. CLP can transiently give rise to B, T, NK and dendritic cells upon 
transplantation [15]. CMP is marked by high CD34 and c-Kit expression, low FcRgII/III 
expression, and lack of Sca-1 in the Lin
-
 population. When CMP further develops into 
granulocyte/monocyte progenitor (GMP), the FcRgII/III expression goes up; when the   
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Figure 1-1.  Conceptual hematopoietic tree of mouse 
 
LT-HSC, Long-term hematopoietic stem cell; ST-HSC, short-term hematopoietic stem 
cell; MPP, multipotent progenitor; CLP, common lymphoid progenitor; CMP, common 
myeloid progenitor; GMP, granulocyte/macrophage progenitor; MEP, 
megakaryocyte/erythrocyte progenitor. 
 
Reprinted with permission. Shizuru, J.A., R.S. Negrin, and I.L. Weissman, 
Hematopoietic stem and progenitor cells: Clinical and preclinical regeneration of the 
hematolymphoid system. Annual Review of Medicine, 2005. 56(1): p. 509-538. 
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CMP develops into megakaryocyte/erythroid progenitor (MEP), it loses FcRgII/III and 
CD34 expression. GMP develops into granulocytes including neutrophils, eosinophils 
and basophils, as well as monocytes that can differentiate into macrophages and dendritic 
cells. MEP can give rise to red blood cells (RBCs) and megakaryocytes. Platelet is the 
fragment of megakaryocyte [13]. 
 
Most of the above processes take place in bone marrow under homeostasis. The 
anatomic structure for T cell development is thymus. Splenic hematopoiesis is different 
between mice and humans. Mouse spleen actively produces RBCs throughout the life. In 
adult human, spleen is not an active hematopoietic organ under steady-state [16], but 
becomes important under stress conditions such as anemia. Under pathological conditions, 
hepatic erythropoiesis also takes place [17]. 
 
In the bone marrow compartment, HSCs are enriched in endosteal surface. It has 
been noted that osteoblast cells within the endosteal region have the potential to produce 
important cytokines to maintain and expand HSCs, including granulocyte 
colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor 
(GM-CSF), interleukine-6 (IL-6), transforming growth factor beta (TGF-, Jagged-1 and 
chemokine ligand 12 (CXCL12) [18]. In two mouse models, bone morphogenetic protein 
(BMP) receptor IA conditional knockout and parathyroid hormone transgenic mice, with 
increased osteoblast cells, the number of HSCs also increase [19, 20]. The fact that HSCs 
are also present in extramedullary tissues such as liver [21] and spleen [9] where 
osteoblast cells are absent, indicates HSC niches other than osteoblast. Anatomically, 
most HSCs mobilized to adult spleen localize adjacent to sinusoids. Even in the bone 
marrow, endosteal niche region is abundant in vasculature, suggesting the role of blood 
vessel as niche [9]. The discovery of osteoblast niche and vascular niche raises a 
question: are there multiple niches that regulate HSCs in different ways, or a common 
mechanism that regulates HSCs in both vascular and endosteal locations? An observation 
that HSCs are consistently found adjacent to CXCL12-secreting cells irrespective of their 
locations in vascular or endosteal region [22] raises the possibility that all HSCs may be 
regulated by a common mechanism [23]. 
 
Even though the majority of HSCs remain confined to the endosteal or vascular 
niches, a small portion of HSCs constantly circulate in the peripheral blood. The amount 
of circulating HSCs in peripheral blood is estimated 100-fold lower than that of bone 
marrow [24], probably 100 to 400 LT-HSCs in the blood of a mouse [25, 26]. The use of 
G-CSF to mobilize HSC from bone marrow for the collection has become a conventional 
clinical practice long before the understanding of the underlying mechanism. 
 
 
Stem Cell Kinetics 
 
 The knowledge on the kinetics of stem cell population is largely obtained from 
mouse. It has been estimated all mammals, including humans, posses 1-2×104 HSCs 
[27]. This estimation is based on the estimated HSC frequency and estimated bone 
marrow cellularity [28]. By single cell transplantation in mouse, the frequency of stem 
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cell is estimated a few out of 10
5
 bone marrow cells (Table A-1), and may vary in 
different genetic backgrounds and ages [29]. 
 
 Among this rare population, only a small fraction are actively cycling at any given 
time point. In a highly enriched HSC population (Lin
-
Sca1
+
c-Kit
+
CD150
+
CD34
-
CD48
-
CD135
-
), 70% cells are dormant, and only 1.6% are in S/G2/M phase [30]. These several 
hundred dividing stem cells must replace billions of RBCs and nonlymphoid peripheral 
blood cells every day [16]. Some studies by BrdU labeling propose the HSC population is 
a group of slow dividing cells that asynchronously enter the cell cycle [31, 32]. A 
mathematical model based on long term BrdU pulse-chase or H2B-GFP chase 
observation indicates 85% of the HSCs divide every 36 days, while the left 15% HSCs 
are highly dormant and divide every 145 days [30, 33]. Several mathematical models 
have been proposed to fit the experimental data [30-33], but all models assume nearly 
fixed cell cycle for the fast dividing and slow dividing population, the validity of which 
assumption is questionable. From the existing knowledge of the immune system, the 
inter-division time interval, or the duration of G0 phase, is unlikely to be homogenous in 
a cell population [34]. This compromises the validity of the proposed models, and the 
actual kinetics of HSCs may be more complicated. 
 
 
Apoptosis of HSC 
 
Mouse Hemogen has been postulated with an anti-apoptotic function in 
hematopoietic cells. A brief introduction on the apoptosis of HSC is included here. 
Mouse gene Hemogen is introduced in Chapter 2. 
 
The apoptotic cells in stem cell population are rare under homeostatic conditions, 
and can be removed rapidly. HSC does respond to at least two common apoptotic signals: 
ionizing radiation (IR) and cytokine deprivation (Figure 1-2).  
 
IR induced apoptosis is related to DNA damage. Generally speaking, apoptosis 
induced by genotoxins is largely due to DNA damage. These DNA damages include [35]: 
covalently modified nucleotides, such as O6-methylguanine, N-methylation, and 
O6-chloroethylation; mismatches; breaks in the backbone including single strand break 
and double strand break (DSB); and DNA cross- linking. IR can create DNA double 
strand break, in response to which ATM-CHK2-p53 will be activated for apoptosis or 
DNA repair. ATR can respond to UV radiation and chemical reagents that stall the DNA 
replication fork [35]. The latter would also be referred as S phase checkpoint. Several 
genes known for their roles in HSC apoptosis in response to IR are listed below. 
 
Bcl-2 overexpression can protect stem cell from IR induced apoptosis [36], but 
knockout animal shows no stem cell abnormality [37]. Puma knockout bone marrow cells 
are IR resistant [38]. The activation of Puma is both p53 dependent and independent [38]. 
The p53 independent activation of Puma is possibly through the transcriptional regulation 
by Slug [39], and Slug knockout animal shows increased sensitivity to IR [40]. The 
protection by Slug is via its antagonizing effect on the pro-apoptotic Puma, and Slug   
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Figure 1-2. Apoptosis of HSC 
 
Ionizing radiation induced apoptosis involves p53, Slug, Puma and Bcl-2. Cytokine may 
protect the HSC from apoptosis via Mcl-1. The expression of Mcl-1 is regulated by SCF. 
 
Sources: Opferman, J.T., et al., Obligate role of anti-apoptotic Mcl-1 in the survival of 
hematopoietic stem cells. Science, 2005. 307(5712): p. 1101-1104. Wu, W.-S., et al., Slug 
antagonizes p53-mediated apoptosis of hematopoietic progenitors by repressing Puma. 
Cell, 2005. 123(4): p. 641-653. 
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itself is also a p53 target gene [39]. 
 
The other pro-apoptotic stress is cytokine deprivation. Under serum free 
conditions, HSCs undergo rapid apoptosis and cannot be protected by overexpression of 
Bcl-2 [41]. This is because HSC needs another signaling from SCF/c-Kit at the same time 
to prevent apoptosis [41]. In coherence with the role of c-Kit and its ligand SCF is the 
Mcl-1 knockout mouse model. Mcl-1 is an anti-apoptotic Bcl-2 family member. Its 
expression in HSC is regulated by SCF signaling, which is required for HSC survival in 
vivo [42]. Mcl-1 knockout animal has anemia and reduced bone marrow cellularity due to 
a loss of the progenitor population [42], and the knockout bone marrow progenitor cells 
cannot survive even in the presence of growth factors [42]. There is also report Mcl-1 is 
required for the UV induced apoptosis [43]. 
 
 
Fetal Hematopoiesis 
 
 Vertebrate hematopoiesis takes place in two waves: a transient primitive 
(embryonic) wave and the definitive (adult) wave. The primitive hematopoiesis is to 
initiate the circulation and provide the initial blood cells; the definitive hematopoiesis is 
to generate more cell types and maintain the HSC pool for lifetime. In humans, the 
primitive hematopoiesis occurs in yolk sac until week 7 of gestation. The definitive 
hematopoiesis starts in fetal liver from week 9 and 24 [16]. Because primitive 
hematopoiesis is primarily erythropoiesis, it is discussed under Erythropoiesis in detail. 
 
 During mouse development, by embryonic day 7.0, a group of cells in the 
posterior primitive streak have developed into hemangioblast, the common precursor of 
blood cells and endothelial cells [44]. Hemangioblast cells migrate to yolk sac, become 
committed endothelial and hematopoietic progenitors, and give rise to blood islands, 
where the first primitive erythrocyte appears [45]. 
 
 The definitive myeloerythroid progenitors can be identified in the yolk sac as 
early as E8.25 [46], soon after the primitive erythroid precursors. Over the next 2 days, 
these progenitors are confined within the yolk sac for proliferation, and migrate to fetal 
liver for terminal differentiation later. Definitive erythrocytes first enter circulation 
between E11.5 and E12.5 [46]. The yolk sac definitive hematopoiesis may also produce 
myeloid and megakaryocytic progenitors [46]. 
 
 The presence of functional HSCs in yolk sac may be controversial. Although yolk 
sac cells can engraft into newborn animals with intrahepatic transplantation, they cannot 
generate adult reconstituting HSC [46]. The quantity of HSC in yolk sac would be low, if 
there is any. The second site for fetal hematopoiesis is aorta-gonadmesonephros (AGM) 
region. HSCs in AGM region may develop in situ rather than being imported from other 
sites, because in vitro cultured para-aortic splanchnopleurae (pSP) tissue from 
precirculation embryos can give rise to transplantable HSCs [47]. Placenta is also an HSC 
pool. There is no consensus on the exact anatomic sites where HSCs reside within the 
placenta. Different HSC markers indicate HSCs may be present within the placental 
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labyrinth, trophoblast giant cell layer, and chorionic plate [48]. Placental HSCs may be 
generated de novo as HSC activity has been detected in the absence of circulation 
[49].This HSC pool is transient, and diminishes while the fetal liver HSC pool expands. It 
is possible the placental HSCs may migrate to fetal liver for definitive hematopoiesis [48]. 
 
 
Erythropoiesis 
 
 As stated above, RBC is the first blood cell type appearing during mouse 
development, detected as early as E7.5 in blood islands. At this stage, the visceral 
endoderm cells can secrete soluble signals such as Indian hedgehog (Ihh) to activate 
erythropoiesis [50]. Wnt/-catenin signaling may regulate the specification process [51]. 
 
 The two waves of erythropoiesis produce primitive and definitive erythrocytes 
respectively. The two populations share some common features, including development 
from lineage restricted progenitors, progressive maturation from nucleated erythroblasts, 
decrease in cell size during maturation, nuclear condensation and finally enucleation 
during late stages [52]. But these two types of erythrocytes are of different developmental 
origins. Primitive erythrocytes originate from posterior plate of mesoderm, and definitive 
erythrocytes are developed from lateral plate [52]. Primitive erythrocytes are larger than 
definitive erythrocytes, express different globin genes, and have higher oxygen carrying 
capacity. At the -globin locus, primitive erythrocytes express Hbb-y and Hbb-bh1, while 
the definitive erythrocytes switch to Hbb-b1 and Hbb-b2 [52]. The yolk sac is the only 
anatomic site for primitive erythrocytes, and definitive erythrocytes are found both in 
yolk sac and fetal liver. As the heart begins to beat at E9.0, primitive erythrocytes enter 
the circulation and continue with the maturation process in bloodstream. Primitive 
erythrocytes develop from nucleated proerythroblast to orthochromatic erythroblast and 
to reticulocytes with loss of nucleoli. This maturation process is also accompanied by loss 
of CD71 expression and gain of Ter119 expression. These mature enucleated primitive 
erythrocytes could live for a long time until birth [52]. 
 
 
Gene Targeting 
 
 
Homologous Recombination 
 
 The fundamental science behind targeted mutagenesis is homologous 
recombination (HR) and DNA double strand break (DSB) repair. Once DSB is detected, 
there are two main pathways available for the purpose of repair, non-homologous end 
joining (NHEJ) and homologous recombination. HR can take place in late S-G2 phase of 
cell cycle, and NHEJ can occur throughout the whole cell cycle [53]. HR is known as the 
error free pathway because a sister chromatid is used as a template for repair. In 
replicating cells, HR is the preferred pathway. The crossover exchange between non-
sister chromatids during meiosis is an example of naturally occurring HR. For a complete 
review, please refer to reference [54]. 
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 The first step in HR mediated repair is strand resection. Once a DSB is created 
either by intrinsic factors like radical oxygen species (ROS) or by extrinsic factors such 
as ionizing radiation (IR), Mre11-Rad50-Nbs1 (MRN) complex acts as a sensor [53]. 
Once MRN complex binds the DSB ends, it recruits ATM/ATR to activate DNA damage 
signaling and promotes strand resection. Strand resection involves generating single 
stranded DNA (ssDNA) at the site of DSB by degrading nucleotides from the 5’ end on 
both sides of the break, making 3’ overhang single-stranded regions. The recombinase 
Rad51 at this stage is loaded to ssDNA and forms a highly extended structure called 
presynaptic filament [54]. The formation of presynaptic filament is a slow process, and 
Brca2 has a role in delivering Rad51 to the ssDNA. The Rad51-ssDNA nucleoprotein 
presynaptic filament then invades into the homologous region on the sister or non-sister 
chromatid by displacing one strand of the template. The invading strand continues 
elongation by repair synthesis, and eventually becomes long enough to cover the entire 
length of the gap. The newly synthesized region then anneals with the far side of the gap, 
forming heteroduplex DNA on each side of the gap. Branch migration converts this 
structure into a molecule with 2 recombinant joints, named Holiday Junction. If both 
Holiday Junctions are resolved in the same direction, the result would be the 
noncrossover original molecule with newly synthesized region; if 2 Holiday Junctions are 
resolved in different directions, the outcome would be crossover of the genetic codes 
between homologous regions [53-55]. 
 
 
Gene Targeting in Mouse 
 
Besides HR, generation of a mouse model with targeted mutation also requires 
successful culture of embryonic stem (ES) cell. In general, ES cells can be cultured in 
petri dish, electroporated with targeting construct, selected for correct homologous 
recombination events, transferred to mouse blastocyst embryos, and transplanted to 
surrogate females. The delivered offspring of the surrogate female is called chimera, 
because part of the individual animal develops from ES cells and part from the original 
blastocyst. If ES cells develop into germ cells, the targeted mutation can be passed to the 
next generation to establish a stable mouse strain carrying this mutation [56]. Details of 
this method are included in Chapter 3. 
 
A problem with the conventional gene knockout strategy is embryonic lethality. 
Although the chimeras and heterozygous animals can be born, sometimes it is impossible 
to obtain the homozygous animals because the targeted gene is so important that the 
homozygous animals die in uterus or even cannot implant. The second problem with 
conventional knockout methodology is the tissue specificity. Some genes are universally 
expressed in many tissues. When such gene is knocked out, it is impossible to distinguish 
the primary effects from the secondary effects and to attribute the phenotypes to specific 
tissues. The third consideration is from the selection cassette used for ES cell screening. 
Constitutive expression of the selection marker may be toxic to the cell or affect the 
phenotypes. One such example is Men1 knockout mouse model. Men1
+/-
 was 
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unexpectedly lethal because the bidirectional transcriptional activity of PGK promoter in 
the selection cassette produced aberrant transcript [57]. 
 
To address the temporal and spatial control problems, the conditional gene 
knockout strategy was developed. This system is developed from phage P1. The loxP site 
is a 34 bp DNA sequence discovered in bacteriophage P1. It consists of two inverted 13 
bp repeats and a central asymmetric 8 bp core region [58]. The phage recombinase Cre 
can mediate recombination between two identical loxP sites. When the two loxP sites are 
in the same orientation, the outcome is excision of the sequence between; when the two 
loxP sites are in the opposite directions, the outcome is inversion of the sequence 
between [59]. In this sense, the selection marker can be excised after selection, and the 
gene can be knocked out only in the desired cell types at the desired time point, whereas 
Cre expression is driven by tissue specific or temporal controllable promoter [60]. 
 
The first batch of gene targeted mouse models came in 1989 [61-63]. By 2001, 
more than 4000 genes had been knocked out [64]. There has been rapid progress since the 
initiation of the International Knockout Mouse Consortium in 2007. By 2011, 
approximately 17000 genes had been disrupted [65]. In 2011, as the second phase of the 
Knockout Mouse Project, another 2500 knockout mice strains are to be developed in 5 
years. 
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CHAPTER 2.    LITERATURE REVIEW OF HEMOGEN AND ORTHOLOGUES 
 
 
 The function of Hemogen (Hemgn) is relatively unexplored. With a focus on 
mouse Hemgn and its orthologues in human and rat in the perspective of comparative 
genomics, this chapter gives a literature review of the published research data and 
analysis in the publicly available databases. 
 
 
Mouse Hemogen 
 
 
Gene Structure 
 
 Hemgn is located in the mouse chromosome 4B1 region. The whole gene spans 
around 19.5 kb, and contains 5 exons. The first exon is non-coding. There is no known 
microRNA in this region according to database search (www.mirbase.org). 
 
 Two transcript variants encoding the same 503 amino acid protein product have 
been identified, one as the hematopoietic tissue isoform and the other as a testis-specific 
isoform. The testis-specific transcript is 2321 bp containing all 5 exons, whereas the 2363 
bp hematopoietic isoform is spliced from exon 2-5. The two isoforms differ in both the 5’ 
and 3’ UTR [66]. 
 
 The first ATG is the translation initiation codon with the sequence AAGATGG, 
consistent with Kozak sequence with A at position -3 and G at position +4. The polyA 
signal is ATTAAA, a common variant of the canonical AATAAA. The protein contains a 
predicted nuclear localization signal (NLS, amino acids 61-78) and a predicted 
coiled-coil domain (amino acids 34-50) in the N-terminus [67]. There is no other 
identifiable functional domain or family member. 
 
 
Expression Pattern 
 
 By in situ hybridization (ISH) with an antisense RNA probe, Hemgn is detected in 
the blood islands of yolk sac and in primitive blood cells as early as E8.5. From E10.5 on, 
Hemgn expression is detected in hepatic primordial with the onset of organogenesis of 
liver. By E11.5, Hemgn expression is found exclusively in the fetal liver, while in 
circulating blood cells it became undetectable. The same expression pattern persists in 
E12.5 and E14.5 embryos [67]. 
 
 In adult animals, Hemgn expression is also examined by ISH. Hemgn is detected 
in the round spermatids in testicle [66], in the red pulp of spleen, where active 
hematopoiesis takes place, but not in the white pulp of spleen [67]. Northern blotting with 
an antisense Hemgn RNA probe does not detect its expression in thymus, brain, heart, 
kidney, liver, lung, skeletal muscle and stomach [67]. Hematopoietic cells are examined 
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with RT-PCR. Hemgn is primarily expressed in Lin
-
and Lin
-
Sca1
+
c-Kit
+
 cells. Cultured 
macrophages and natural killer cells also show weak expression, but no expression is 
detected in other differentiated blood lineages including CD3
+
 T cell, B220
+
 B cell, 
Ter119
+
 erythrocyte and Gr1
+
 granulocyte [67]. However, it is not specifically noted 
whether these differentiated cells are isolated from bone marrow or peripheral blood, 
which is discussed in Chapter 5. In sum, Hemgn is selectively expressed in hematopoietic 
progenitor cells, but diminishes in mature and differentiated cell types. 
 
 
Gene Regulation 
 
 By luciferase assay, a minimum promoter region from -831 to +196 is identified, 
and a 184 bp fragment in 5’ UTR may contain critical regulatory elements for Hemgn 
transcription. This 184 bp sequence contains 3 GATA boxes (TATAA). Gata-1, but not 
Gata-2, binds and transactivates Hemgn promoter [68]. 
 
 Hemgn has been identified as a direct transcriptional target of Hoxb4 [69]. Hoxb4 
can promote mouse hematopoietic stem cell self-renewal in vitro and ex vivo. When 
hematopoietic stem cells or hematopoietic progenitor cells (HPCs) are transduced with 
Hoxb4, Hemgn is found highly up-regulated. In a chromatin immunoprecipitation (CHIP) 
assay, Hoxb4 binds Hemgn promoter directly and regulats its transcription, as indicated 
by luciferase activities in MEL cell line. There are also multiple Hoxb4 binding sites 
TAAT in Hemgn promoter region [69]. Functional assays also show that Hemgn is a 
downstream target gene of Hoxb4. Hemgn transduced HSCs/HPCs gain growth 
advantage over wild-type cells, similar to Hoxb4 transduced cells [69]. 
 
 There are multiple predicted miRNA target sites in 3’ UTR. Some with the 
highest score in miRanda Target database (www.microrna.org) include miR-377, 
miR-208a, miR-208b, miR-499, miR-128, miR-542-3p. Among these microRNAs, 
miR-128 can target Bmi-1 to inhibit glioma stem cell self-renewal [70], but whether this 
is also true for HSC is unknown. 
 
 
Putative Functions of Hemgn 
 
 The exact function of Hemgn is less known. Whether the predicted NLS is 
functional and indispensible for its nuclear localization has not been experimentally 
tested. Hemgn is transported to nucleus of COS-7 cell upon transfection [67]. The nuclear 
localization might imply its possible function in transcription, chromatin structure, DNA 
repair, RNA splicing and other biological processes in the nucleus. The other predicted 
motif is the coiled-coil domain. The function of -helical coiled-coil structure is to 
mediate subunit oligomerization or other type of protein-protein interaction through ionic 
interaction or hydrophobic interaction [71, 72]. A typical coiled-coil motif consists of 
helices of 7 residues in each. The number of the 7 residue repeats can go up to 200 in a 
protein [71]. With analysis by NCOILS (embnet.vital-it.ch/software/COILS_form.html) 
and COILS/PCOILS (toolkit.tuebingen.mpg.de/pcoils) programs, mouse Hemgn may 
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contain 2 such repeats between amino acid 34 to 50 with high score (score>0.9). In 
contrast, the same programs can only find human homologous sequence with very low 
score for coiled-coil structure formation (score<0.2). Because no other motifs like the 
canonical DNA or RNA binding domains are identified, it is less likely Hemgn binds 
DNA or RNA directly to regulate transcription or splicing. It is possible Hemgn interacts 
with other nuclear proteins through its coiled-coil motif and carry out its function. Hemgn 
function may also be regulated by posttranslational modification. Serine 380 has been 
characterized as a phosphorylation site in Ba/F3 cell line [73]. However, the 
physiological or pathological significance of S380 phosphorylation is not known. From 
published literatures, Hemgn may be related to apoptosis and HSC self-renewal as stated 
below. 
 
 Anti-apoptosis. Hemgn overexpression in bone marrow progenitor cells has been 
shown with the ability to protect these cells from cytokine withdrawal induced apoptosis. 
5-FU treated mouse bone marrow cells are transduced with Hemgn retroviral vector or 
control vectors, and cultured for additional 6 days in the presence of cytokine 
supplements. After 16 hours culture in medium with 1% FBS but without cytokine 
supplements, the Annexin V
+
 cells in Hemgn transduced cells are less than 20% while in 
control the percentage is more than 50%. Hoxb4 transduction shows a stronger protection 
effect on the progenitor cells [69]. It is yet unclear what upstream or downstream factors 
of Hemgn might be accounted for this protective effect. 
 
 HSC self-renewal. Overexpression of Hemgn can recapitulate the Hoxb4 
mediated HSC expansion. Hemgn transduced cells show growth advantage in both liquid 
culture and colony assay. Secondary colony assay is a measurement of the self-renewal 
ability of stem cells. When 5-FU treated bone marrow cells are transduced with Hemgn 
and cultured in M3434 medium, increased secondary colony number is seen [69]. This 
phenotype may be due to the anti-apoptotic function of Hemgn [69]. Meanwhile, Hoxb4 
mediated HSC expansion is impaired, but not totally ablated, when Hemgn is silenced by 
RNA interference (RNAi), indicating Hemgn independent function of Hoxb4 [69]. The 
involvement of Hemgn in Hoxb4 function initiated my interest in the physiological and 
pathological roles of Hemgn itself in hematopoiesis. 
 
 
Rat Hemogen/RP59 
 
 
Gene Structure 
 
 Rat Hemogen, also known as RP59, locates in chromosome 5q22 region. The 
gene spans 10 kb, and consists of 4 exons. There is only one transcript encoding a 514 
amino acids protein. Rat RP59 is 75% identical to mouse Hemogen in protein alignment, 
but is only 46% identical to human Hemogen. 
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Expression Pattern 
 
 By ISH and immunohistochemistry (IHC), RP59 expression is detected in [74]: 
 
1. The yolk sac of day 9 post coitum (p.c.) rat embryos, corresponding to mouse 
E7;  
2. Extraembryonic mesodermal layers with its prospective blood islands; 
3. The intraembryonic primary ectoderm at day 9 p.c., including the primitive 
streak; 
4. Well-developed blood islands containing mainly erythropoietic cells at day 
12 p.c.; 
5. Fetal liver erythroblast cells, megakaryocytes and circulating cells at day 17 
p.c.; 
6. Bone marrow and spleen red pulp of 5-day-old rat; 
7. Young osteoblast [75]; 
8. Newly secreted tooth enamel and ameloblast [76]. 
 
The expression pattern of Hemgn is better characterized in rat than in mouse. In 
late prenatal stages, RP59 is also found in peripheral circulating blood [74]. The same 
may not be true for mouse [77]. Hemgn is not expressed in the blood cell of E11.5 mouse 
embryo, and the expression level is very low in adult mouse peripheral blood [67]. 
Similar to mouse, RP59 is absent in most tissue, among which including fetal spleen, 
liver (after birth), and the white pulp of adult spleen [74]. 
 
Different from the cell line based assay of mouse Hemgn, IHC staining of rat 
bone marrow shows cell type specific subcellular localization of the protein. It 
predominantly localizes in the cell periphery of erythroblast, and in the nucleus of 
osteoblast and megakaryocyte [75].  
 
 
Human Hemogen/EDAG 
 
 Human Hemogen, known as Erythroid Differentiation Associated Gene (EDAG, 
or EDAG-1) is a homologue of mouse Hemogen with 46% identity. The sequences of 
NLS and coiled-coil motif are partly conserved between species. However, as stated 
above, programs only predict very low score for the coiled-coil structure formation in 
human EDAG. 
 
 
Gene Structure 
 
 Human EDAG/Hemgn is located in chromosome 9q22.33 region. The gene spans 
around 18 kb, and consists of 6 exons of which the first two exons are non-coding. There 
are two transcript variants. The long transcript contains all 6 exons and exon 2 is missing 
in the short isoform. The 2 transcripts produce the same 484 amino acids protein product, 
which shares 46% identity with mouse Hemgn. 
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Expression Pattern 
 
 The expression pattern of human EDAG is similar to mouse Hemogen. It has been 
detected by northern blotting at high level in adult bone marrow and fetal liver [67], but 
not in other tissues including spleen, lymph node, thymus, adult liver, heart, skeletal 
muscle, kidney, pancreas, tonsil, colon and peripheral blood mononuclear cells (PBMC) 
[68]. Child thymus shows low level of expression [67]. 
 
 Pathological expression is found in AML and ALL patients’ PBMC. Measured by 
real-time PCR in 10 AML patient samples, a positive correlation is reported between 
Gata-1 and EDAG transcription in myeloblast (R=0.93) [68]. This is consistent with the 
observation mouse Hemgn may be transcriptionally regulated by Gata-1. Mouse Hemgn 
promoter region contains multiple Gata binding motifs where Gata-1 actually binds [68]. 
Whether Gata-1 also binds human EDAG promoter is not known. 
 
 
Putative Functions 
 
 An EDAG transgenic mouse model driven by the human CD11a promoter 
displays increased myelopoiesis and impaired lymphopoiesis [77]. The transgenic mice 
develop no abnormality up until 6 months. However by 6-24 months, their leukocyte 
numbers in peripheral blood are 2-fold higher than that of control animals. The increased 
number of mature granulocytes primarily accounts for this change. Flow cytometry 
reveals a significant increase of the CD11b
+
Gr1
+
 granulocytes. In contrast, the number of 
monocytic cells does not change dramatically. Bone marrow of the transgenic animal is 
found with hyperplasia in dominance of granulocytes. Spleens show a similar increase of 
the myeloid cells. These results indicate the onset of myeloid hyperplasia in the 
transgenic animals, with increase in the number of granulocytes [77]. Although both bone 
marrow and spleen share a similar phenotype, their responses during in vitro cell culture 
are quite different. When cultured in Methocult 3534 with supplement of stem cell factor 
(SCF), IL-3 and IL-6, the CFU-GM numbers are comparable between the transgenic 
animals and control animals. However in the same assay, splenocytes of the transgenic 
mice show a 2-fold increase in the colony number. When stimulated with GM-CSF 
supporting the growth of myeloid progenitors, transgenic splenocytes also give rise to 
2.5-fold colony numbers [77]. These results suggest the differentiation rate of CMP to 
granulocytes is normal, but there is a promotion in extramedullary myelopoiesis. 
 
 In contrast to the increase in granulocytes, the number of B220
+
 lymphoid cells 
decreases in the transgenic bone marrow. Flow cytometry analysis reveals a 95% 
reduction in B220
+
CD25
+
 pre-B II cells and 50% decrease in the B220
+
IgM
+
 
immature/mature B cells within the bone marrow compartment. The B220
+
c-Kit
+
 
pro/pre-B I cells are comparable between transgenic and control animals. These 
observations indicate the pro/pre-B I to pre-B II transition is hindered by constitutive 
EDAG expression [77]. The transgenic mice also display reduction in thymus cellularity 
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and CD4
+
CD8
+
 population. There is a dramatic increase of the CD44
+
CD25
-
 cells within 
the CD4
-
CD8
-
 compartment, indicating early T cells are arrested at DN I stage [77]. 
 
As a result of the myeloid hyperplasia, 34% of the transgenic mice die of severe 
organ infiltration by neutrophils during the period of 6-24 months. The moribund animals 
develop severe splenomegaly and the spleen weight shows a 3-fold increase. Morphology 
of the liver is abnormal, with large pale regions on the surface. Necropsy shows prevalent 
infiltration of liver, lung and kidney by neutrophils [77].  
 
The physiological significance of this gene is unclear, but leukemic breakpoints in 
human chromosome 9q22 involving the EDAG locus implies its potential role in 
leukemia development [67]. There are several putative tumor associated genes in 9q22 
region: NR4A3 is a member of nuclear hormone receptor family implicated in regulation 
of proliferation, differentiation and T cell apoptosis [78]; Foxe1 is the genetic 
determinant in certain thyroid carcinoma cases [79]; and EDAG is one of the potential 
leukemogenic genes. Most associated leukemia cases reported are AML, and the most 
frequent lesion type is deletion involving a break point in the 9q22 region [80]. Among 
950 cancer cell lines screened, EDAG mRNA is detected in several human leukemic cell 
lines including K562, KU812 [81], both carrying Bcr-Abl translocation [82], as well as in 
Bcr-Abl
-
 [83] human erythroleukemia cell line HEL 92.1.7 [81]. The expression level in 
bone marrow mononuclear cells of AML patients with complete remission is also 
significantly lower than those with no remission after therapy [84].  
 
 Similar to the mouse Hemgn, human EDAG has been proposed for an anti-
apoptotic function. Overexpression of human EDAG in IL-3 dependent pro-B cell line 
Ba/F3 promotes survival in the absence of IL-3 by activation of the NF-B signaling, and 
up-regulating c-Myc, Bcl-2 and Bcl-xL, as determined by Western blotting [85]; Bcl-2 
down-regulation is also seen in EDAG knockdown K562 cells, measured by 
semiquantitative RT-PCR [84]. This anti-apoptotic effect has been attributed to its 
physical interaction with nucleophosmin (NPM or NPM-1), which prevents the 
degradation of NPM [86]. The interaction between the two proteins is confirmed by co-
immunoprecipitation (Co-IP) in K562 cells with monoclonal NPM antibody. In K562 
cells, silencing of EDAG is also associated with decreased NPM protein level [86]. 
 
 
Limitations of Previous Studies 
 
 
The Ectopic Expression and Overexpression Systems 
 
 Previous studies are mostly based on overexpression and ectopic expression 
systems. However gain of function study is different from the loss of function study. It is 
necessary to address the differences between the two systems and some intrinsic 
problems with ectopic expression and overexpression models. 
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 Loss of function model and gain of function model are the two sides of a coin. 
However, effects observed in gain of function model may not guarantee an opposite 
observation in the other. For example, overexpression of Hoxb4 leads to strong 
proliferation of HSC population [87], but the gene knockout model shows no obvious 
phenotype; overexpression of the anti-apoptotic factor Bcl-2 can protect HSC from 
ionizing radiation induced apoptosis [36], but the knockout mouse does not present 
defects in HSC [37]. 
 
 One explanation is gain of non-physiological function when too much protein is 
expressed and binds to its non-physiological partners or substrates [88]. In the 
perspective of chemistry, the association and dissociation of a protein and its partners are 
under delicate equilibrium under homeostatic conditions. Increase in the concentration of 
specific protein will enhance not only the specific interaction with its physiological 
substrates, but also the interaction with other partners of low specificity and low affinity, 
especially in ectopic expression system, where the physiological co-factors might be 
absent. A positive result from overexpression or ectopic expression model might be non-
physiological. This is why loss of function study can complement the overexpression 
model for the physiological research. Gene knockdown by RNAi or inhibitors may elicit 
the concerns on incomplete knockdown and off target effect, but gene knockout model is 
relatively clean and specific. Although a lack of phenotype may be attributed to reasons 
like genetic redundancy, a positive phenotype in gene knockout model unequivocally 
demonstrates the physiological function of specific gene. 
 
 
Conservation across Species 
 
 The human gene EDAG has been studied in mouse cells. Human EDAG is 
ectopically expressed in the hematopoietic system of the transgenic mouse model [77]; 
and the anti-apoptotic function of EDAG is also tested in murine Ba/F3 cell line [85]; its 
function in the erythroid and megakeryocyte development is studied in 32D cell line [89], 
an IL-3 dependent myeloid cell line established from C3He/J mice injected with the 
Friend murine leukemia virus. None of these studies are carried out in human cells. 
 
 Indeed there have been transgenic mouse models of human genes, such as 
transgenic mouse of human -globin [90]. However, such examples are highly conserved 
across species. The sequence identity of -globin between mouse and human is 80%; 
human and mouse K14 keratin are identical by 90% [91]. The validity of such across 
species transgenic models is based on the assumption that, the transgenic genes, though 
not in their original cell contexts, should behave similarly as they were. The above 
mentioned examples can satisfy this assumption by their highly conserved sequences 
across species. But the homology between mouse Hemgn and human EDAG is only 46%. 
Even by comparing only the first 124 amino acids of the two proteins, which region may 
be required for the protein-protein interaction and where the predicted NLS and 
coiled-coil domain locate, the identity is 58% only. This fact is not a guarantee the human 
EDAG may function still in the same way in murine cells. The information obtained from 
such chimeric system might be limited, or even misleading. Instead, data of human 
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EDAG and mouse Hemgn obtained respectively from the correct species may make 
better sense than those cross-species assays. It is also necessary to answer the question 
whether mouse Hemgn is the functional equivalence of human EDAG. 
 
 To address the above two problems, a mouse Hemgn knockout mouse model 
would be an appropriate tool to study its physiological function. 
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CHAPTER 3.    MATERIALS AND METHODS 
 
 
 This chapter introduces all materials and methods used in this study. Brief 
introduction of the methodology is included where needed. 
 
 
Design of the Targeting Allele 
 
 The initial design process is a database and software based bioinformatics 
research. This section includes basic step-by-step instructions on genomic databases 
analysis. However the design process by nature should be considered case by case. The 
method described below is gene specific, and may not be applied to other genes without 
modification. 
 
 
Positions of loxP Sites 
 
Bioinformatic resources were found in Ensemble Genome Browser 
(www.ensembl.org). In the location view of mouse Hemgn, the page was configurated by 
turning on the following tracks: KO Alleles, KO Designs, GeneTrap, BAC map, Mouse 
miRNAs, miRNAs (miRBase), Reg. Feats, cisRED, RFAM ncRNAs, All Repeats, 
InterPro, miRanda Target and VISTA Enhancer. All available information listed in 
Mouse Genome Informatics (www.informatics.jax.org) was also checked. 
 
With the help of InterPro track, a general idea of which exons to be knocked out 
was formulated based on the structure of the protein. The mRNA sequence of Hemgn 
was retrieved to VectorNTI from NCBI (www.ncbi.nlm.nih.gov) with its Accession 
Number. Exon sequences were manually deleted in different combinations. The new 
open reading frame (ORF) products were aligned to the wild-type protein product to 
figure out the best knockout strategy. loxP sites were placed at least 150 bp from the 
exons without interruption of the regulatory elements listed above. 
 
The sequence data of the gene with 10 kp upstream of the proposed 5’ loxP and 
10 kb downstream of the 3’ loxP was retrieved from Ensemble Genome Browser in 
Genbank format as txt file, with selection of Repeat Features and Gene Information in 
Genbank options. The coordination of the sequence was reset in VectorNIT to its 
coordination in Ensemble database. 
 
 
Enzymes and Probes for Southern Blotting 
 
 With the facility of VectorNTI, the candidate enzymes for Southern blotting were 
selected. These enzymes cut only in the flanking sequences of the homology arms but not 
within the homology arms. Each enzyme was further analyzed for the expected band 
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sizes. Enzymes with less than 1 kb difference between the wild-type and targeted allele 
were excluded. 
 
 The flanking sequences of the homology arms were screened for around 400 bp 
probes free from Repeat Features coverage. These candidate probes were searched by 
Blast (blast.ncbi.nlm.nih.gov) to check the specificity. For each end of the targeting 
locus, 2 probes were initially designed but only one was used in this study. 
 
 
The Targeting Construct 
 
 The protocols for generating targeting construct was developed from Dr. Pentao 
Liu’s protocol, published on Frederick Natioinal Laboratory for Cancer Research website 
(ncifrederick.cancer.gov/research/brb/protocol.aspx). The bacteria mediated 
recombineering system is based on E.coli strain EL350 expressing  phage RED system 
[92]. The whole process is summarized in Figure 3-1. 
 
 
Miniprep for BAC Clone 
 
 BAC clone RP23-259O2 was obtained from Children’s Hospital Oakland 
Research Institute (Oakland, CA). The BAC containing bacteria cells were cultured in LB 
with 12.5 g/ml chloramphenicol. The cells were lysed and neutralized by Qiagen 
miniprep kit (Qiagen, #27104) according to the manufacturer’s instruction. DNA was 
precipitated by adding equal volume of isopropanol. The tube was inverted repeatedly to 
mix (25-50 times), left at room temperature for incubation of 10 minutes, and then spun 
at 14000 g for 10 minutes. The DNA pellet was washed with 70% methanol, left air-dry 
for 10-20 minutes, and resuspended in 20-50 l TE buffer. The DNA was dissolved by 
incubation at 50C for 30 minutes to an hour. The DNA concentration was measured with 
Nanodrop. 
 
 
Retrieving Construct and Mini-targeting Constructs 
 
 The retrieving vector VP101, and two vectors for mini targeting PL451 and 
PL452 were obtained from previous lab members. All constructs were generated by PCR, 
restriction enzyme digestion and ligation, and were sequenced before use. 
 
 For all PCR reactions, the initial denaturing was 5 minutes at 95C, and the final 
extension was 10 minutes at 72C. The annealing temperatures and extension times 
within cycles were different, as listed in Table A-2. PCR primer sets and the restriction 
enzymes used are summarized in Table A-3. All oligos synthesis and sequencing were 
done at St Jude Children’s Research Hospital Hartwell Center. The PCR equipment was 
MJ Research PTC-200 Peltier Thermal Cycler. 
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Figure 3-1.  Schematic flowchart of generating knockout targeting construct 
 
2 retrieving arms were ligated into vector VP101, and the resulting construct were 
electroporated into EL350 for BAC retrieval. 2 mini targeting arms were ligated into 
vector PL452 to make the first mini targeting construct. Another 2 mini targeting arms 
were cloned into vector PL451 to make the second mini targeting construct. The first 
mini targeting construct were electroporated into EL350 to insert the first loxP cassette. 
After arabinose induction, the second mini targeting construct were subsequently 
electroporated into EL350 to insert the second FRT-loxP cassette. 
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Transforming DNA into EL350 
 
EL350 cells used in this study were all cultured at 32C. Other bacteria strains 
were cultured at 37C. Transformation of EL350 was carried out by electroporation. 
Overnight culture of EL350 cells were centrifuged at 5000 rpm for 6 minutes at 0C. The 
cells were then washed with 888 l ice-cold water for 3 times, resuspended in 50 l ice-
cold water, and transferred into a cuvette (BioRad, #165-2089). BAC DNA (50-200 ng) 
or other DNA vector (200 ng) was added to the cuvette. Electroporation was carried out 
using Biorad GenePulser with following conditions: 1.75 kV, 25 F, 200 . Time 
constant was around 4.0. The electroporated cells were incubated in 1 ml SOC 
(Invitrogen, #15544-034) at 32C for 1 hour, and cultured on agar plate with appropriate 
antibiotics (12.5 g/ml chloramphenicol, 100 g/ml ampicillin, and/or 25 g/ml 
kanamycin) overnight. Individual colonies were picked up to check the integrity of the 
vector by restriction enzyme digestion. 
 
 
EL350 Recombinase Induction and Transformation 
 
The vectors were purified by electroporation into the original EL350 again before 
each recombination. 10 ml EL350 cells containing BAC or intermediate vector were 
transferred to a new flask for a 15 minutes water bath at 42C with shaking. Immediately 
after the 42C incubation, the flask was put into ice-water mixture, shaken continuously 
and left in wet ice for another10-20 minutes. The cells were then washed, electroporated 
and selected as stated above. 
 
 
BAC Retrieval 
 
BAC DNA was electroporated into the original EL350 and selected with 
chloramphenicol. The BAC containing EL350 was cultured in 5 ml LB medium with 
choloramphenicol. The cells were heatshocked and electroporated with the retrieving 
vector (derived from VP101) as stated above. The transformed cells were cultured under 
ampicillin selection. At least 20 individual clones were picked up and the plasmids were 
extracted using Qiagen miniprep kit. The plasmid samples were analyzed on 1% agarose 
gel with empty VP101 vector as control. The clones with larger plasmid size were further 
digested with restriction enzymes to check the integrity. For the purpose of discussion, 
this positive clone is named Retrieved Vector. 
 
 
Insertion of the First loxP Site 
 
The Retrieved Vector containing EL350 was cultured in 5 ml LB medium with 
ampicillin, heatshocked and electroporated with the first mini-targeting vector (derived 
from PL452) as stated above. Transformed cells were cultured under ampicillin (100 
g/ml) and kanamycin (25 g/ml) double selection. Individual clones were picked up and 
the plasmids were extracted and digested to check the presence of neo cassette. To make 
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sure of single copy in each clone, plasmid was electroporated into the original EL350 
strain and selected again for ampicillin and kanamycin double resistant. Single colonies 
were finally picked up and checked by restriction enzyme digestion. 
 
 
Popping out Neo Cassette 
 
A single colony of the targeted cell (with the first loxP site and the neo cassette) 
was inoculated to 5 ml LB for overnight culture, then transferred to a 10 ml LB culture 
for 2-3 hours until OD600=0.5. 100 l 10% L-arabinose (Sigma Aldrich, #A-3256) was 
added to the culture (final concentration 0.1%) and Cre induction was kept for one hour. 
The diluted culture was plated to ampicillin plates. On the next day, several colonies were 
picked up to 96-well plate for additional culture of 2-3 hours. An aliquot of the culture 
was copied to another 96-well plate with kanamycin to screen for the kanamycin 
sensitive clones. The kanamycin sensitive clones were identified on the next day visually 
by the clear LB. 
 
 
Insertion of the Second loxP Site 
 
EL350 cells with the above vector (with the first loxP site, without neo cassette) 
were cultured in 5 ml LB medium with ampicillin and heatshocked as stated above. The 
second mini-targeting vector (derived from PL451) was electroporated into the cultured 
cells. Elecroporated cells were selected for ampicilllin and kanamycin double resistant 
clones. All exons and loxP sites were sequenced with appropriate primer sets in Table 
A-3. The final DNA targeting construct was prepared by maxiprep (Qiagen, #12963).  
 
 
ES Cell Targeting and Screening 
 
 The ES cell culture and gene targeting protocols were developed from the 
instruction manual of The Mouse Kit (LEXICON, #745002) with modification. 
 
 
Cells and Reagents 
 
 W9.5 ES cells were obtained from Dr. Peter McKinnon’s lab. The specific 
passage of the cell line was not noted. Feeder cells (mouse embryonic fibroblast cells) 
and other reagents were provided in Embryomax knockout kit (Millipore, #ES-100). The 
feeder medium consisted of Dulbecco's Modified Eagle Medium (DMEM) with 7% FBS, 
2 mM L-glutamine, 50 U/ml penicillin, and 50 g/ml streptomycin. ES cell medium 
consisted of DMEM with 15% FBS, 100 mM -mecaptoethanol, 2 mM L-glutamine, 50 
U/ml penicillin, and 50 g/ml streptomycin. ESGRO (Millipore, ESG1107) was added at 
1000 U/ml. 
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Feeder Cell and ES Cell Preparation 
 
The cell culture plates were coated with gelatin at room temperature for at least 2 
hours before use. Feeder cells were seeded in gelatin coated 10 cm plates at 5×106 
cells/plate, and in 96-well plates at 3.3×104 cells/well. The feeder cells were cultured for 
at least 5 days prior to plating ES cells.  
 
ES cells were cultured on feeder cells in ES cell medium for 3 days. ES cell 
medium was replenished daily. When the plate reached 70-80% confluence, the medium 
was refreshed again. Two hours later, the cells were rinsed twice with PBS, trypsinized 
for 15 minutes and vigorously triturated by rapidly pipetting up and down for 40-50 
strokes. The ES cells were spun down at 1000 rpm for 7 minutes, resuspended in ES cell 
medium, and split to 3 feeder plates for subculturing. The ES cell medium was changed 
daily. 
 
 
Electroporation of ES Cells 
 
The targeting construct was linearized with overnight digestion by NotI. Prior to 
harvesting the cells, both ES cells and feeder cells were cultured in fresh ES cell medium 
for 2 hours. ES cell plates were rinsed twice with PBS, and trypsinized for 20 minutes. 
ES cells were pooled and gently pipetted to make single cell suspension. The total 
number of cells was counted with hemacytometer. The cells were centrifuged and 
resuspended in PBS to make a suspension of 11×106 cells/ml. Electroporation was 
carried out in the cuvette (0.4 cm electrode gap). To each cuvette, 15-20 g linerized 
targeting construct DNA and 0.9 ml ES cell suspension were added and mixed gently by 
pipetting. Electroporation was performed at 230 V, 500 F capacitance. The time 
constant was in the range of 5.8 to 7.0 msec. The electroporated ES cells were pooled, 
resuspended in ES cell medium and dispensed to feeder plates. One plate of ES cells 
electroporated with control PGKneo cassette was also prepared. The electroporated cells 
were cultured for 24 hours before starting the selection. 
 
 
Selection of ES Cell Clones 
 
One day after the electroporation, ES cells were cultured in the medium with 200 
g/ml G418 and 2 M ganciclovir. The selective medium was replenished every day for 
the first 4 days then only every other day thereafter. The selection continued for 11 days, 
until the resistant colonies became visible to the naked eye. To pick up colonies, each 
gene targeting plate was rinsed twice with PBS, and covered with 8 ml PBS finally. 
Individual colony was circled with the pipette tip in the border, and the feeder layer 
below was cut by the pipette tip. The colony was detached and drawn into the pipette tip 
and transferred to a 96-well plate with 30 l trypsin, one colony per well. Only small 
colonies were picked up. The picked colonies were trypsinized for 10 minutes, after 
which 70 l ES cell medium was added to inactivate trypsin. The cells were 
disaggregated by pipetting up and down 40 times. Then the trypsinized cells were 
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transferred to another 96-well feeder plate containing 100 l ES cell medium. The ES cell 
clones were cultured for the next 2 days, and copied to another 96-well plate for DNA 
extraction. 
 
 
DNA Extraction in 96-well Plate 
 
When the majority of ES cell clones were fully confluent, the cells were washed 
twice with PBS. The plates were then placed at -80C overnight and brought to room 
temperature to warm up for 5 minutes. To each well, 50 l lysis buffer (10 mM Tris pH 
7.5, 10 mM EDTA pH 8, 10 mM NaCl, 0.5% sarcosyl, 1 mg/ml proteinase K) was added. 
The plates were incubated overnight at 60C in a humidified chamber. The next day, 100 
l cold 100% ethanol (with 75 mM NaCl) was added to each well. The plates were left at 
room temperature for 30 minutes until the DNA became visible. The plates were gently 
inverted to drain the ethanol, and washed with 70% ethanol for 3 times. The plates were 
left uncovered at 37C until moisture was gone. The DNA was finally dissolved in water.  
 
 
Southern Probe Labeling 
 
The probes were generated by PCR (Table A-2, Table A-3), and purified with 
QIAquick PCR purification kit (Qiagen, #28104). 
 
25 ng probe DNA was dissolved in nuclease free water. The total volume was 
adjusted to 33 l. The DNA was denatured in boiling water bath for 5 minutes, and then 
quickly placed in ice for 5 minutes. The tube was centrifuged briefly at 4C. The probes 
were labeled with NEBlot labeling kit (New England BioLabs, #N1500S) in designated 
area with protection. The following reagents were added to DNA: 5 l 
octadeoxyribonucleotides in 10x Labeling Buffer, 6 l dNTP mixture (2 l of dATP, 
dTTP, and dGTP), 5 l α 32P dCTP (3000 Ci/mmol, 50 Ci) and 1 l DNA Polymerase 
I-Klenow Fragment (5 units). The reaction was incubated at 37C for 1 hour, and 
terminated by adding 5 l of 0.2 M EDTA (pH 8.0). The probes were purified with 
Illustra G-50 Micro Column (GE Healthcare, #28903408) by centrifugation. The activity 
of labeled probes was measured with radioactivity counter (Bioscan QC 2000). The 
readout was above 1×106 cpm. 
 
 
Southern Blotting and Development 
 
For a typical Southern blotting, 10 g genomic DNA was digested overnight. For 
mini-Southern blotting, approximately 2 g DNA was digested. To each DNA sample, 35 
l digestion cocktail (1x restriction buffer specified for the enzyme being used, 1 mM 
spermidine, 100 g/ml BSA, 50 g/ml RNase, and 15 units of enzyme) was added and 
mixed well. The enzymes used in this study were SpeI and NheI. The plates or tubes were 
sealed and incubated overnight at appropriate temperature for the enzymes in a 
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humidified chamber. On the next day, the digested DNA was loaded to 1% agarose gel 
for electrophoresis. The DNA was transferred from gel to Hybond membrane overnight 
and crosslinked with the membrane by UV. The membrane was incubated with 25 ml 
hybrid solution (Hybrisol, Millipore, #S4040) for prehybridization at 42C in a cylinder 
with rotation. 
 
The probes were labeled as stated above. The labeled probes were added to the 
hybrid cylinder and incubated overnight at 42C with rotation. The membrane was then 
washed with 500 ml 3x SSC/0.5% SDS for 30 minutes at 65C, followed by another 500 
ml 0.5x SSC/0.5% SDS for 30 minutes at 65C. The radioactivity on the membrane was 
checked by Geiger counter. The membrane was exposed to phosphor screen (Molecular 
Dynamics) overnight. The phosphor screen was scanned with a phosphorimager 
(STORM 860 Molecular Imager, Molecular Dynamics). The clones with the desired 
recombination were sent for karyotyping at the cytogenetic lab. 
 
 
Blastocyst Injection and Mouse Breeding 
 
 Blastocyst micro-injection and surgeries were done by technicians in St Jude 
Children’s Research Hospital transgenic core facility. The procedures are under animal 
protocol 191 Appendix I. 
 
 
Blastocyst Micro-injection 
 
 For each blastocyst micro-injection, at least 20 blastocysts were collected in 
DMEM with HEPES from the uterine horns of pregnant C57BL/6 females on day 3.5 
post coitum. ES cells were trypsinized and disaggregated by vigorous strokes to make 
single cell suspension. The cells were washed with ES medium before injection. Under 
high power magnification, 10 to 20 small and round ES cells were selected, drawn into 
the injection needle and expelled into the blastocyst cavity. The injected blastocysts were 
transferred to the uterine horn of female CD1 mice. After delivery and weaning of the 
pups, the foster females were euthanized. 
 
 
Mouse Breeding 
 
Chimeras were bred to wild-type C57BL/6 animals. Those with germline 
transmission were told by the coat color of the offspring. Only pups with agouti coat were 
kept for further breeding. All agouti animals were genotyped by PCR. Breeding pairs 
were set up according to Figure 3-2. Heterozygous animals were obtained by crossing 
the agouti animals with E2A-Cre strain (The Jackson Laboratory, #003724), and 
knockout animals were obtained by interbreeding of heterozygous animals. The wild-type 
offspring were kept as 129 and C57BL/6 outbred controls. Genotypes of the animals were 
confirmed by Southern blotting and PCR (Table A-2, Table A-3). 
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Figure 3-2. Breeding diagram 
 
Agouti pups from the chimera parent were bred with wild-type C57BL/6 animals. F1 
animals were PCR screened and interbred to generate the homozygous flox/flox F2 
animals. To generate the homozygous knockout animals, agouti pups were bred with 
E2A-Cre strain; F1 were PCR screened and bred to wild-type C57BL/6 to expand the 
colony; F2 were PCR screened again and interbred to produce homozygous knockout 
animals. 
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Mouse Phenotyping 
 
 
Colony Assay 
 
 Mouse bone marrow cells were harvested in 2% FBS, counted with 
hemacytometer, and diluted to 2×106 cells/ml in Iscove's Modified Dulbecco's Medium 
with 2% FBS. 0.4 ml cell suspension was added to 4 ml MethoCult GF M3334 (Stemcell 
Technologies, #03334) or M3434 (Stemcell Technologies, #03434) medium for triplicate 
cultures, and tubes were thoroughly vortexed. To each 35 mm culture dish, 1.1 ml 
medium was gently dispensed. The 35 mm dishes were placed into a 10 cm petri dish 
with one extra uncovered dish containing sterile water to maintain humidity during 
culture. CFU-E numbers were counted 3 days later. When using MethoCult GF M3434 
(Stemcell Technologies, #03434), total colony numbers were counted 10 days later. 
 
 
Competitive Repopulation 
 
 Recipient animals (C57BL/6J, The Jackson Laboratory, #000664, 6-8 weeks 
female) were given 1100 rad Cs137 radiation one day prior to the transplant, and fed on 
baytril water. Bone marrow cells of the donor animals and the competitors (CD45.1 
B6.SJL-PtprcaPepcb/BoyJ, The Jackson Laboratory, #002014, 8-10 weeks) were 
harvested from the femurs and tibias in 2% FBS. Bone marrow cells were filtered with 
40m nylon mesh. Cell numbers were then counted with hemacytometer. Donor cells and 
competitor cells were mixed with a 1:1 ratio, and resuspended in appropriate volume of 
ice-cold 2% FBS. The volume was determined by the number of recipients. Each 
recipient animal received 500 l cell suspension via tail vein injection. In ionizing 
radiation sensitivity assay, each recipient received 10 million donor cells and 10 million 
competitor cells. Some transplant recipients later received 2 G or 4 G irradiation again 
after full reconstitution at 20 weeks. The peripheral blood was obtained from the 
recipients by retro-orbital bleeding at the 8 weeks, 14 weeks and 20 weeks after the 
transplant. White cells were analyzed by staining with Mac1, Gr1, B220 and CD3 
antibodies to tell the relative contribution of CD45.2 and CD45.1 cells in each lineage by 
flow cytometry. 
 
 
Platelet Aggregation Assay 
 
Blood was collected by cardiac puncture from anesthetized animals in the 
presence of 60 l 3.8% acid citrate dextrose (ACD) buffer (6.8 mM citric acid, 11.2 mM 
trisodium citrate, and 24 mM glucose, pH 6.5). Whole blood was diluted in 400 l 
Tyrode’s buffer (0.1% BSA, 0.1% glucose, 2 mM MgCl2, 137.5 mM NaCl, 12 mM 
NaHCO3, 2.6 mM KCl, pH 7.4) and centrifuged at 600 g for 3 minutes. The cloudy 
supernatant was collected and centrifuged for 5 minutes at 1300 g to pellet platelets. 
Washed platelets were counted on FORCYTE Hematology Analyzer, and diluted to 
2.5×10
5
/l in Tyrode’s buffer. 300 l diluted platelets was transferred into each glass 
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tube with magnetic stir bars. Diluted patelet samples were put into a Fibrintimer 4 
channel aggregometer (APACT Laborgeräte und Analysensysteme). Aggregation was 
induced by adding 0.01 U or 0.1 U thrombin, 0.3 nmol or 1.5 nmol ADP (final 
concentration1 M or 5 M), or 600 ng collagen (final concentration 2 g/ml) into 300 
l washed platelets respectively while stirring. Light transmission of the platelet solution 
was recorded for a 4 minute period. 
 
 
Reticulocyte Staining 
 
Thiazole Orange (Sigma Aldrich, #390062) was dissolved in ethanol as 1 mg/ml 
(2000x) stock solution and kept at -20C. 2 l peripheral blood was stained in 1 ml 0.5 
g/ml Thiazole Orange in PBS for 90 minutes at room temperature, washed twice with 
PBS and analyzed by flow cytometry in the FITC channel. 
 
 
Hematocrit Measurement 
 
Peripheral blood was collected by retro-orbital bleeding with micro-hematocrit 
capillary tubes. The tubes were planted on tube sealer (SEAL EASE®, Becton Dickinson 
and Company, #36-1050) to seal one end of the capillary. Capillary tubes were spun at 
4000 rpm for 5 minutes in a micro-hematocrit centrifuge. The sealed end of the tube was 
aligned to the center of micro-capillary reader. The percentage of red cells was recorded 
by rotating the reading plate. 
 
 
Phenylhydrazine Treatment and Bleeding 
 
 Phenylhydrazine (Sigma Aldrich, #78670) was diluted to 5 mg/ml in PBS. Each 
animal received 60 mg/kg body weight phenylhydrazine by intraperitoneal injection for 2 
consecutive days. Anemia condition was also induced by retro-orbital bleeding of 350 l 
blood daily for 4 consecutive days. Hematocrit measurement and reticulocyte staining 
were carried out as stated above. 
 
 
Intracellular Staining 
 
Fresh bone marrow cells or splenocytes were stained with surface markers first. 
The cells were then fixed in 2% PFA and permeablize the cells with 0.5% saponin for 20 
minutes or with cold acetone for 20 minutes. Non-specific binding sites were blocked 
with human IgG for 30 minutes. The cells were stained with 1 g/ml primary Hemogen 
antibody (Santa Cruz biotechnology, M180) at 4C overnight in a humid chamber. On the 
next day, the cells were washed with 2% FBS, stained with the secondary antibody 
(Invitrogen, #A31632) for 1 hour, and analyzed by flow cytometry. 
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RNA Extraction and Real-time PCR 
 
 RNA was extracted from sorted cells with RNAqueous kit (Ambion, #AM1931) 
according to the manufacturer’s instruction. Cells were pelleted and resuspended in 100 
l lysis solution. After adding 50 l ethanol, the tube was vortexed briefly. The lysate 
was applied to the micro-filter for a centrifugation at maximum speed for 10 seconds. 
The filter was washed with solution 1, followed by wash with solution 2/3 for twice, and 
centrifuged at maximum speed for 1 minute. RNA was finally eluted from the filter in 10 
l elution solution, and quantified with Nanodrop. 
 
 Reverse transcription was performed with Superscript VILO kit (Invitrogen, 
#11754). For each reaction, 4 l VILO mix, 2 l enzyme mix, and 4 l water were added 
to the 10 l RNA extract. The tube was briefly vortexed, and incubated at room 
temperature for 10 minutes, followed by additional 60 minutes incubation at 42C. The 
tube was spun during the incubation to rid the lid from water. The reaction was 
terminated by heating at 85C for 5 minutes. The reverse transcribed DNA was stored 
at -20C until use. 
 
 Real-time PCR was carried out with SYBR Green Master Mix (Applied 
Biosystems, #4367659). For each reaction of 25 l, 12.5 l master mix, 2.5 l diluted 
primers for Hemgn (Qiagen, #QT00106099) or GAPDH (Qiagen, #QT01658692), 8 l 
water and 2 l diluted template were added to each well. PCR was performed in a 
StepOnePlus real-time PCR system (Applied Biosystems). 
 
 
Cell Culture and Separation 
 
 Ba/F3 and 32D cells were cultured in RPMI with 10% FBS and 10 ng/ml IL-3. 
Primary bone marrow cells were cultured in DMEM with 15% FBS and cytokine 
supplement (20 ng/ml IL-3, 50 ng/ml IL-6 and 50 ng/ml SCF, PEPRO TECH, #200-06, 
#213-13, #250-03). The cytokine supplement was refreshed every 3 days. GPE-86 cells, 
NIH3T3 cells and 293T cells were cultured in DMEM with 10% FBS. 
 
 Lin
-
 bone marrow cells were enriched by lineage cell depletion kit (Miltenyi 
Biotec, #130090858). Mouse bone marrow cells were harvested by flushing both femurs 
and tibias in 2% FBS. The cells were filtered through 40 m filter, counted and pelleted 
as stated above. Every 10
7
 total cells were incubated with 10 l biotin labeled antibody 
cocktail in 40 l magnetic-activating cell sorting (MACS) buffer (2 mM EDTA and 0.5% 
BSA in PBS) for 10 minutes at 4C, followed by incubation with 20 l anti-biotin 
microbeads for 15 minutes at 4C. The cells were washed and finally resuspended in 500 
l MACS buffer, and went through LS separation column (Miltenyi Biotec, #130042401) 
Cells in the flowthrough were pelleted and resuspended in culture medium with cytokine 
supplement. 
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 The retroviral vector producer cell lines, transduced Ba/F3 and 32D cell lines 
were sorted by flow cytometry based on GFP expression. 
 
 
Cytokine Deprivation 
 
 Apoptosis was induced by cytokine deprivation on lineage depleted bone marrow 
cells, Ba/F3 and 32D cells. Prior to cytokine deprivation, dead cells in the culture were 
eliminated with a dead cell removal kit (Miltenyi Biotec, #130090101). The cultured cells 
were washed with PBS, pelleted and incubated in 100 l dead cell removal microbeads 
for 15 minutes at room temperature, and then went through MACS. Viable cells were 
collected from the flowthrough. Ba/F3 and 32D cells were cultured for 20 hours in RPMI 
with 2% FBS but without IL-3 supplement. For primary cells, lineage depleted cells were 
cultured in DMEM with 2% FBS without cytokine supplement for 24 hours. Apoptosis 
was then measured by Annexin V and DAPI staining. 
 
 
Annexin V Staining 
 
A total number of 3×10
5
 cells (total cell count=live+dead) were washed with PBS, 
and incubated in 100 l Annexin binding buffer (10 mM HEPES, 0.9% NaCl, 2.5 mM 
CaCl2, 0.1% BSA) containing 10 l Annexin V-APC (Becton Dickson, #550474) for 15 
minutes at room temperature in the dark. 300 l additional cold binding buffer and 10 l 
DAPI solution (0.25 mg/ml in PBS) were added to the tube. Samples went through 40 m 
nylon mesh and were placed on ice. The apoptotic cells were analyzed by flow cytometry 
soon after completion of staining. 
 
 
Statistics 
 
 Statistics were done with two-tailed t-test. In platelet aggregation assay, 
difference factors (f1) and similarity factors (f2) were calculated with the absorption 
values according to reference [93]. Two curves are considered similar if f1<15 and f2>50. 
Rt and Tt are the absorption values of wild-type and knockout samples at different time 
points respectively, and n is the number of data points. 
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Western Blot and Antibodies 
 
 
Lysate Preparation 
 
Protein extracts were prepared with M-PER mammalian protein extraction 
reagent (Pierce, #78501) supplemented with the protease inhibitors (Pierce, #78430). The 
cells were pelleted by centrifugation at 2500 g for 10 minutes at 4°C. The volume of cell 
pellet was estimated by the wet weight. 1 mg wet weight was translated into 1 l in 
volume. M-PER reagent was added in 10-fold volume of the cell pellet. The cells were 
lysed by gently inverting the tube at 4°C for 10 minutes, and then centrifuged at 
maximum speed at 4°C for 15 minutes. The supernatant was transferred to a clean tube 
and kept on ice until use or storage. 
 
 
Cytoplasmic and Nuclear Protein Extraction 
 
The procedure was carried out with NE-PER nuclear and cytoplasmic extraction 
reagents (Thermo Scientific, #78833). The protocol was adopted from the manufacturer’s 
instruction by extra washing step. 
 
Total 10
7
 cells were pelleted by centrifugation at 500 g for 2 minutes. Ice-cold 
CER I buffer was added to the cell pellet. The tube was vortexed vigorously on the 
highest setting for 15 seconds, and left incubated on ice for 10 minutes. Ice-cold CER II 
was added to the tube. The tube was vortexed for 5 seconds, and then incubated on ice for 
1 minute. The tube was vortexed again and centrifuged for 5 minutes at maximum speed. 
The supernatant (cytoplasmic extract) was immediately transferred to a pre-chilled tube, 
and placed on ice until use or storage. The pellet was washed with ice-cold PBS for 3 
times to minimize cross contamination. The insoluble pellet fraction was resuspended in 
ice-cold NER. The tube underwent continuous vortexing for 15 seconds every 10 minutes, 
for a total of 40 minutes. The pellet was then centrifuged at maximum speed for 10 
minutes. The supernatant (nuclear extract) fraction was immediately transferred to a pre-
chilled tube, and placed on ice. The protein concentration was quantified by Nanodrop 
with BioRad Protein Assay Dye Reagent (BioRad, #500-0006). 
 
 
Immunoblotting 
 
In each reaction, 13 l LDS Sample Buffer (Invitrogen, #NP0008), 5 l Sample 
Reducing Agent (Invitrogen, #NP0004) and 30 g protein extract were added. The total 
volume was adjusted to 35 l with water. The mixture was heated at 70°C for 10 minutes 
and loaded to 4-12% gradient NuPAGE Bis-Tris gel (Invitrogen, #NP0323). 
Electrophoresis was carried out at 120 V until the dye ran out of the gel. The proteins 
were transferred at 30 V for 1 hour to 0.45 m PVDF membrane (Life Technologies, 
#LC2002) that was pre-activated with methanol. The membrane was washed in 0.1% 
PBST, and then blocked with 5% milk in PBST for 1 hour. The membrane was cut in 
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reference to the visible markers below the bands of 75 kD and 50 kD. The membrane was 
incubated with primary antibodies (1:1000 dilution in 5% milk, 200 ng/ml) respectively 
at 4C overnight. On the next day, the membrane was wash twice with 5% milk, and 
incubated with secondary antibodies (1:1000 dilution in 5% milk) for 1 hour. The 
primary antibodies used were Hemogen (Santa Cruz biotechnology, M180), HDAC1 
(Santa Cruz biotechnology, 10E2), GAPDH (Millipore, MAB374). Secondary antibodies 
were goat anti-rabbit IgG-HRP (sc-2004, Santa Cruz biotechnology) for M180 and goat 
anti-mouse IgG-HRP (sc-2060, Santa Cruz biotechnology) for 10E2 and MAB374.  
 
Bands were detected using HRP labeled secondary antibodies and developed with 
ECL Prime Western blotting detection reagent (GE Healthcare, #2232). The blot was 
exposed in FluorChem M imaging system (ProteinSimple). 
 
 
Mutagenesis 
 
 
PCR Mutagenesis 
 
 PCR was carried out with high fidelity polymerase Phusion (New England 
BioLabs, #M0530). PCR primers and conditions are listed in Table A-4 and Table A-5 
respectively. Final PCR fragments CC or NLS were cloned into MSCV-IRES-GFP 
retroviral vector backbone with SpeI and DraIII. The constructs were then sequenced. 
 
 
Transient Transfection 
 
293T cells were seeded in 10 cm dishes at 8×106 cells/plate in the morning. 
Transfection was carried out 6 hours later. For one plate, 10 g retroviral vector plasmid 
DNA was mixed with 5 g Old-GagPol, 1 g pCAG-VSVG, and appropriate volume of 
H2O to make a final volume of 450 l. After mixing well the plasmids, 50 l 2.5 M 
CaCl2 was added and mixed well. Additional 500 l 2×HBSS was added to DNA-CaCl2 
dropwise while vortexing. 1 ml DNA-CaCl2-HBSS mixture was added dropwise to each 
plate and mixed well by swirling the plate. The cells were cultured in transfection 
mixture for 18 hours. On the next day, the plates were washed twice with PBS, overlaid 
with 10 ml fresh medium and incubated for 48 hours. On day 4, the supernatant was 
collected and filtered through 0.22 m membrane (Millipore, #SCGP00525), and kept at 
4C or on ice until use. 
 
 
Producer Cell Line 
 
GPE-86 cells were seeded in 10 cm dishes at 5×105 cells/plate in the morning for 
6 hours expansion. 5 ml filtered supernatant from transient transfection was mixed with 5 
ml medium (for one dish). Polybrene was added to a final concentration of 6 g/ml. The 
diluted supernatant was applied to GPE-86 cells gently. The cells were transduced with 
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retroviral vector containing supernatant twice daily for the next 5 days. Two days after 
the last transduction, GFP
+
 cells were sorted and expanded. After the initial expansion, 
the producer cells were sorted for the second time. 
 
 
Retroviral Transduction 
 
For the transduction of primary cells, bone marrow cells were cultured in DMEM 
with 10% FBS, 50 ng/ml SCF, 20 ng/ml IL-3, and 50 ng/ml IL-6 for 2 days. For cell lines, 
no pre-stimulation was carried out. All 6-well plates were coated with RetroNectin 
(Takara, #T100) at room temperature for 2 hours or 4C overnight, and blocked with 2% 
BSA for 1 hour. 
 
 Primary cells or cell lines were seeded at 5×105 cells/well. The filtered retroviral 
vector supernatant with cytokines (if necessary) and polybrene (final concentration 6 
g/ml) was applied to the cells. The plates were centrifuged at 2000 rpm for 30 minutes. 
The cells were hit twice daily for 2 consecutive days. Two days later, the medium was 
changed to fresh DMEM with 10% FBS and cytokines if required. The cells were then 
sorted or analyzed by flow cytometry based on GFP expression.  
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CHAPTER 4.    RESULTS 
 
 
Generation of Hemgn Knockout Mouse Model 
 
The wild-type mouse Hemgn allele spans 19.5 kb in the genome, and consists of 5 
exons. The wild-type protein has 503 amino acids. Our targeting construct flanks the 
exons 3-5, with one loxP site at 510 bp upstream of exon 3, and the other with a 
PGK-Neo selection cassette at 302 bp downstream of exon 5 (Figure 4-1A). By this 
targeting strategy, 95% of the C-terminal sequence of the protein was truncated, leaving 
only 26 residual amino acids at the N-terminus. 
 
The targeting construct was generated via BAC recombination in bacteria. Exons 
in the construct were sequenced before ES cell targeting. The construct was linearized 
with NotI and electroporated into W9.5 ES cells. By using a combination of G418 and 
ganciclovir selection, single ES cell clones were obtained and expanded for PCR and 
Southern blot screening. Clones with the desired recombination were checked for 
karyotypes and injected into blastocysts. The chimerism of the animals born was 
indicated by the coat color. Only animals with high chimerism were kept for further 
breeding. The germline transmitted pups were identified by the agouti coat color. Correct 
gene targeting was confirmed by PCR genotyping and Southern blotting (Figure 4-1B, 
C). 
 
Progenies of chimeric animals were bred with the E2A-Cre mouse strain to 
produce a germline null allele. The E2A promoter has a ubiquitous expression pattern 
including the germline. Germline deletion of floxed sequence was confirmed by 
sequencing across the Cre-mediated recombination junction. Hemgn
+/-
 animals were 
interbred to produce knockout animals. Ablation of the protein in hematopoietic cells and 
round spermatids was confirmed by flow cytometry, Western blot and IHC staining with 
a polyclonal antibody recognizing Hemgn amino acids 181-360 (Figure4-1D, Figure 
4-2A). By Western blot analysis, the molecular weight of Hemgn was approximately 75 
kD in bone marrow cells, whereas no signal was detected in Hemgn knockout cells. 
 
 
Expression Pattern of Mouse Hemgn 
 
Although the expression pattern of rat Hemgn is well established [74, 76], its 
expression in mouse tissues has not been documented in detail. Sites known to express 
Hemgn include bone marrow progenitor cells, spleen and testis [66, 67, 94]. By IHC 
staining, we confirmed Hemgn expression in spleen red pulp, bone marrow, and round 
spermatids in the testicle (Figure 4-2B). 
 
The expression of Hemgn mRNA was examined by quantitative real time PCR at 
various developmental stages of hematopoietic cells in the bone marrow compartment 
(Figure 4-2C). During hematopoiesis, Hemgn was first detected in the CD34
-
LSK long 
term hematopoietic stem cells (LT-HSC) and the CD34
+
LSK short term hematopoietic   
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Figure 4-1. Targeting strategy of Hemgn conditional allele 
 
(A) Hemgn wild-type, conditional and null alleles. ATG is in exon 2; exon 1 is not 
shown. Two loxP sites flank exon 3-5. The null allele was generated by crossing with an 
E2A-Cre strain. Black and grey bars indicate probes for the Southern blot; arrows point 
to genotyping primers. (B) Southern blot of the tail DNA from germline transmitted pups 
(lanes #4, 9, 12) and control pup (lane #11). (C) PCR genotyping of wild-type, Hemgn 
null and heterozygous mice. The null band was sequenced. (D) Ablation of the Hemgn 
protein in knockout animal was confirmed by Western blot with a polyclonal antibody. 
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Figure 4-2. Endogenous Hemgn expression pattern 
 
(A) Hemgn was both detected by intracellular staining in bone marrow and spleen 
Ter119
+
 cells. (B) Hemgn was detected by immunohistochemical staining in 
erythroblasts and megakaryocytes in bone marrow, red pulp of spleen, and round 
spermatids in testicle. (C) Real-time PCR showed Hemgn expression in LT-HSCs, 
ST-HSCs, CMPs, MEPs and erythroid cells, but low expression in B cells, T cells, NK 
cells, macrophages and granulocytes in bone marrow. The internal control of real-time 
PCR was GAPDH. 
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stem cells (ST-HSC). Stem cells can further differentiate into common myeloid 
progenitor (CMP) and common lymphoid progenitor (CLP) cells. Hemgn expression was 
up-regulated in the CMPs, which can give rise to both granulocyte/monocyte progenitor 
(GMP) and megakaryocyte/erythroid progenitor (MEP) cells. Hemgn expression was 
down-regulated in GMPs, and was not further detected in mature granulocytes. Mature 
macrophages continued to weakly express Hemgn. However, Hemgn was further up-
regulated in MEPs, and the majority of Hemgn
+
 cells were Ter119
+
 erythroid cells. In 
contrast, the expression level of Hemgn was very low in mature lymphoid lineages, 
including B cells, T cells and NK cells, which is consistent with published data [67]. The 
expression of Hemgn in CLPs was not examined specifically, but has been reported to be 
lower than that in HSCs [95]. 
 
This expression pattern triggered our interest in further exploring the erythroid 
compartment. Previous studies on the expression of Hemgn in erythroid lineages are 
contradictory, reporting both the presence and absence of Hemgn expression in Ter119
+
 
erythroid cells [67, 94]. In our flow cytometry analysis, most Hemgn expressing cells 
were Ter119
+
, both in the bone marrow and spleen (Figure 4-2A). Ter119
+
 erythroid 
cells are heterogeneous populations that undergo multistep maturation. In combination 
with the erythroid development marker CD44, Ter119
+
 cells can be subdivided into 
several stages [96]. Normal erythropoiesis begins with the pro-erythroblast stage (Ter119 
low or medium), and after gaining Ter119 expression, goes through the basophilic 
erythroblast, polychromatic erythroblast, and orthochromatic erythroblast stages, finally 
becoming reticulocytes and mature red blood cells (RBC). Flow cytometry analysis 
confirmed the expression of Hemgn in the Ter119
-
CD71
+
 progenitor population (Figure 
4-3A) that has BFU-E and CFU-E activity. A further analysis of Ter119
+
 erythroid cells 
with CD44 showed that Hemgn expression was gradually up-regulated in basophilic 
erythroblasts and peaked in polychromatic erythroblasts and orthochromatic 
erythroblasts, but was lost in mature RBCs (Figure 4-3B, C). Hemgn expression was also 
confirmed in megakaryocytes via IHC staining of bone marrow sections (Figure 4-2B). 
 
 
Normal Steady-state Hematopoiesis and Stress Erythropoiesis 
 
Hemgn knockout animals were viable and fertile, phenotypically 
indistinguishable from wild-type mice. We measured hematopoiesis in peripheral blood, 
bone marrow, thymus and spleen. 
 
Peripheral blood was examined by determining the complete blood count under 
steady-state conditions (Figure 4-4A). RBC count, white blood cell count, platelet count, 
mean corpuscular hemoglobin, and mean corpuscular volume were normal in knockout 
animals. There were no abnormalities in the morphology of RBCs in the blood smear 
(Figure 4-4B). Hematocrit was measured by centrifuging blood in capillary tubes for 
better accuracy. The percentage of reticulocytes in the peripheral blood was determined 
by thiazole orange staining and flow cytometry. Thiazole orange is a reliable marker as it 
can stain the residual RNA component in reticulocytes [97]. The percentage of 
reticulocytes was not significantly different from that of wild-type animals, and was  
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Figure 4-3. Hemgn expression in erythroblasts 
 
(A) Hemgn expression in the Ter119
-
CD71
+
 erythroid progenitors by intracellular 
staining. (B) Gating of Ter119
+
 erythroblast based on cell size and CD44 expression. 
Gate II: basophilic erythroblast; Gate III: polychromatic erythroblast; Gate IV: 
orthochromatic erythroblast; Gate V: enucleated red blood cell. (C) Hemgn expression by 
intracellular staining at different stages of erythroblast development. 
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Figure 4-4. Steady-state hematopoiesis of Hemgn knockout mice 
 
(A) Complete blood count of peripheral blood (p>0.05 by t-test for each parameter). 
Reticylocytes were stained with thiazole orange (TO). HCT: hematocrit; WBC: white 
blood cell count; MCV: mean corpuscular volume; MCH: mean corpuscular hemoglobin; 
RBC: red blood cell count; PLT: platelet count. (B) Blood smear of Hemgn knockout and 
wild-type mice. (C) Distribution of all blood lineages in peripheral blood, bone marrow, 
spleen and thymus (p>0.05 for each lineage).  
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below the level indicative of anemia. The presence and distribution of different cell types 
in each of the hematopoietic organs were checked by staining with different lineage 
markers such as B220, CD3, CD4, CD8, Gr1 and Mac1 (Figure 4-4C). In the bone 
marrow, spleen peripheral blood and thymus, the percentage of each major lineage was 
normal. In general, steady-state hematopoiesis did not show significant defects. 
 
The normal development of myeloid and lymphoid cells under steady-state 
conditions in Hemgn knockout animals might be related to the relatively low expression 
level of Hemgn in GMPs and CLPs. In contrast, because of the high expression of 
Hemgn in MEPs and erythrocytes, erythropoiesis was examined in detail. Different 
developmental stages of erythroid cells (basophilic, polychromatic and orthochromatic 
erythroblasts) were compared in bone marrow cells from knockout and wild-type animals, 
based on Ter119 and CD44 expression. The percentages of all subpopulations were 
normal in the knockout animals (Figure 4-5A). 
 
Unlike in humans, the spleen is an important hematopoietic organ under normal 
steady-state conditions in the mouse. Anemic conditions are often associated with 
enlarged spleens and increased extramedullary hematopoiesis. The spleen weight of 
Hemgn knockout mice was normal (Figure 4-5B), and IHC staining confirmed the 
presence of Gata-1
+
 erythrocytes in the spleen (data not shown), indicating normal 
extramedullary hematopoiesis and lack of anemia. At the erythroid progenitor level, 
CFU-E number was measured in the bone marrow compartment by in vitro culture in an 
M3334 methylcellulose medium. Wild-type and Hemgn knockout bone marrow cells 
produced the same numbers of CFU-E (Figure 4-5C). 
 
Erythropoietin (EPO) signaling is important for erythropoiesis. Under certain 
stress conditions such as bleeding, the in vivo EPO level can rise and stimulate the 
regeneration of RBCs. To determine the stress erythropoiesis of Hemgn knockout 
animals in response to elevated EPO signaling, animals were given bleeding stress or 
treated with phenylhydrazine, a compound used to induce hemolytic anemia [98]. After 2 
doses of phenylhydrazine, the hematocrit and reticulocyte production in the peripheral 
blood were monitored during the regeneration phase. Both wild-type and Hemgn 
knockout animals produced reticulocytes and regenerated RBCs in this induced anemia 
model (Figure 4-5D). However, phenylhydrazine treatment can cause some RBCs in the 
peripheral blood to gain autofluorescence in flow cytometry, which may interrupt the real 
thiazole orange signal for reticulocytes. To bypass this problem, animals were retro-
orbitally bled (350 l) for 4 consecutive days. Similar reticulocyte production and RBC 
regeneration were observed (Figure 4-5E) on bleeding stress, indicating that Hemgn 
knockout animals can respond robustly to the elevated EPO signaling. 
 
 
Normal Platelet Function 
 
 Because Hemgn is expressed at relatively high levels in megakaryocytes, we 
analyzed the megakaryocytes and platelets. No difference between wild-type and Hemgn 
knockout animals was reported by the full necropsy examination in the number or the  
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Figure 4-5. Steady-state and stress erythropoiesis 
 
(A) Distribution of basophilic (II), polychromatic (III), orthochromatic (IV) erythroblasts 
in the bone marrow Ter119
+
 population based on cell size and CD44 expression (p>0.05 
by t-test for each population). (B) Spleen weight of Hemgn knockout and wild-type 
animals (p=0.75). (C) CFU-E numbers in bone marrow (p=0.52). Cells were grown in 
M3334 culture. (D) HCT and reticulocyte regeneration upon phenylhydrazine induced 
anemia (p>0.05 for each time point). (E) HCT and reticulocyte regeneration upon 
bleeding (p>0.05 for each time point). Reticulocytes were stained with thiazole orange.  
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size of megakaryocytes. Platelet counts were generally lower than expected, but 
comparable between knockout and wild-type animals (Figure 4-4A). 
 
 The function of platelets was tested by an aggregation assay [99]. Purified 
platelets were stimulated by thrombin, adenosine diphosphate (ADP) or collagen, which 
activate platelets through different receptors. Murine thrombin interacts with PAR-3 and 
PAR-4 receptors; ADP interacts with P2Y receptors; and collagen interacts with GP 
receptors [100]. In response to the stimuli of these reagents, platelets should form clots so 
that aggregation can be monitored by changes in light transmission through the platelet 
solution. In response to these reagents, platelets from both wild-type and knockout 
animals aggregated completely at comparable rates (Figure 4-6), indicating normal 
function of platelets of Hemgn knockout animals. 
 
 
Normal Stem Cell Function and Defect in Lymphoid Reconstitution 
 
The expression level of Hemgn is lower in the HSCs than in erythroid progenitors 
and erythroblast cells, but still significantly higher than in other differentiated blood cells. 
Hemgn is a direct target of Hoxb4 in the ex vivo expansion of HSCs, which may point to 
a potential function in the HSC and HPC populations [69]. To determine the function of 
Hemgn in these cell populations, progenitor and stem cell activity was assessed by the 
colony forming assay in vitro and competitive repopulation of lethally irradiated animals 
in vivo. 
 
Dysfunction of HSCs or HPCs often leads to bone marrow dysplasia with 
decreased cellularity. However, this did not occur in Hemgn knockout animals. Total 
nucleated bone marrow cell number for 2 femurs and 2 tibias of each mouse revealed no 
significant differences between wild-type and knockout animals (Figure 4-7A). To test 
the colony forming ability of bone marrow progenitor cells, isolated bone marrow cells 
were cultured in an M3434 methylcellulose medium in the presence of SCF, IL-3, IL-6 
and EPO. Bone marrow cells from wild-type and knockout animals gave rise to the same 
number of CFUs (Figure 4-7B), indicating normal steady-state kinetics in progenitor 
cells. This observation was consistent with the distribution of various progenitor and stem 
cell populations defined by surface markers in the bone marrow. Flow cytometry analysis 
showed that the percentages of HSC, CMP, MEP, and erythroid progenitors were 
comparable between wild-type and Hemgn knockout animals in the bone marrow 
compartment (Figure 4-7C). 
 
Colony formation is a measurement of progenitor activity, whereas the surface 
marker profile gives information only on the phenotypes but not the functions of stem 
cells and progenitor cells. The gold standard to test the function of HSCs is competitive 
repopulation of lethally irradiated animals. Donor bone marrow cells from Hemgn 
knockout animals were mixed with competitor cells carrying the CD45.1 surface marker 
in a 1:1 ratio, and transplanted into lethally irradiated recipients. By 20 weeks after 
transplantation, all blood lineages in the peripheral blood should be derived from the 
transplanted stem cells. At this point, the peripheral blood profile is generally accepted as   
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Figure 4-6. Platelet aggregation 
 
Purified platelets from Hemgn knockout and wild-type animals were stimulated by 
collagen (f1=2.7, f2=82.1), ADP (f1=9.3, f2=56.2 for 1M; f1=7.5, f2=61.6 for 5M) and 
thrombin (f1=2.1, f2=83.8 for 0.01U; f1=2.7, f2=71.3for 0.1U). Aggregation was 
monitored by change in light transmission of the platelet solution. Difference factors (f1) 
and similarity factors (f2) were calculated according to reference [93]. Two curves are 
considered similar if f1<15 and f2>50. 
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Figure 4-7. Progenitors in the bone marrow 
 
(A) Bone marrow cellularity of 2 femurs and 2 tibias of each animal (p=0.7 by t-test). (B) 
CFU numbers of knockout and wild-type bone marrow cells cultured in an M3434 
medium (p=0.83). (C) Percentages of LSK (p=0.11), CMP (p=0.59), MEP (p=0.21) and 
Ter119
-
CD71
+
 (p=0.3) erythroid progenitors in bone marrow, measured by flow 
cytometry. 
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a reflection of reconstitution in the bone marrow compartment. Although myeloid cells, 
including macrophages and granulocytes, showed robust reconstitution from both the 
wild-type and Hemgn knockout cells, the contribution of Hemgn knockout cells to the 
lymphoid lineages, including B and T cells was slightly but significantly lower than that 
in the wild-type group (Figure 4-8A). This indicates a subtle defect of Hemgn knockout 
cells in lymphoid reconstitution upon transplantation. 
 
 
Sensitivity to Apoptotic Stresses 
 
It has been proposed that Hemgn is associated with apoptosis [69, 85, 86]. 
Overexpression of EDAG in the murine pro-B Ba/F3 cell line can protect the cell from 
IL-3 withdrawal induced apoptosis [85]; knockdown of EDAG in K562 cells can increase 
imatinib induced apoptosis [86]; and overexpression of Hemgn in mouse bone marrow 
cells can protect cells from cytokine deprivation induced apoptosis [69]. These evidences 
lead to the question of whether Hemgn knockout cells are more sensitive to apoptotic 
stresses than wild-type cells. 
 
Mouse bone marrow progenitors may be sensitive to apoptotic stresses such as 
ionizing radiation and cytokine deprivation. Knockout of the anti-apoptotic Bcl-2 family 
member Mcl-1 results in lethality because of bone marrow failure [42], and heterozygous 
animals are sensitive to -IR. Slug knockout mice show increased sensitivity to -IR [40]. 
Radiation induced apoptosis is generally thought to be dependent on p53. Slug provides 
protection via its antagonizing effect on the pro-apoptotic Puma, and Slug itself is also a 
p53 target gene [39]. -IR can create DNA double strand breaks, in response to which the 
ATM-CHK2-p53 pathway is activated. However the ataxia telangiectasia (ATR) 
responds to UV radiation and chemical reagents that stall the DNA replication fork [35]. 
 
 To determine the susceptibility of Hemgn knockout HSCs and HPCs to p53 
dependent cell death, low dose -IR was given to the reconstituted competitive transplant 
recipient animals. The lethally irradiated recipients initially received Hemgn knockout 
and CD45.1 competitor bone marrow cells in a 1:1 ratio to minimize the possible effects 
of cell extrinsic factors. When the recipients reached a long-term reconstitution after 20 
weeks, they were exposed to 4 G or 2 G -IR to induce HSC apoptosis. If Hemgn 
knockout cells were more sensitive to -IR, their contribution to the peripheral blood 
would decrease after the insult. Another 20 weeks after the low dose -IR exposure, 
Hemgn knockout cells continued to make a significant contribution to all lineages in the 
peripheral blood, and to the same extent that the wild-type controls did (Figure 4-8B). 
No systemic difference was found between animals receiving 2 G and 4 G IR, implying 
that Hemgn knockout bone marrow cells are not more sensitive to p53 dependent 
apoptotic stress than wild-type cells. 
 
 On the other hand, cytokine deprivation induces apoptosis in p53 independent 
pathways [101]. Fresh Hemgn knockout progenitor cells were enriched by lineage 
depletion, and cultured in the absence of cytokine supplements for 24 hours. Apoptosis  
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Figure 4-8. Sensitivity to ionizing radiation and cytokine deprivation 
 
(A) Competitive repopulation in peripheral blood at 20 weeks post transplantation, before 
low dose ionizing radiation (p<0.01 for B220 and CD3 cells, p>0.05 for Gr1 and Mac1 
cells by t-test). Each recipient received 10
7
 CD45.2 cells and 10
7
 CD45.1 cells. (B) 
Peripheral blood profile at 20 weeks after 2 G or 4 G ionizing radiation (p>0.05 for each 
lineage). (C) Percentage of Annexin V
+
 cells in Lin
-
 progenitor population after cytokine 
deprivation (p=0.27). Cells were cultured for 24 hours in DMEM with 2% FBS but 
without cytokine supplements, and stained with Annexin V and DAPI.
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was then analyzed by Annexin V and DAPI staining. No accelerated cell death was 
observed in Hemgn knockout progenitor cells (Figure 4-8C). 
 
In summary, there was no increased sensitivity to p53 dependent or independent 
apoptotic stresses in Hemgn knockout primary cells. 
 
 
Partial Impairment of Hoxb4 Function 
 
Hemgn was originally identified as a Hoxb4 direct target in HSC ex vivo 
expansion. Knockdown of Hemgn impairs the Hoxb4 mediated expansion, but does not 
totally ablate its function, indicating that mechanisms other than Hemgn may also be 
responsible for Hoxb4 mediated expansion [69]. Similarly, when bone marrow 
progenitors were transduced with Hoxb4 in Hemgn knockout and wild-type backgrounds, 
complete knockout of Hemgn resulted in an almost 50% reduction in the secondary 
colony numbers (Figure B-1). This loss of function study in combination with the 
previously published RNAi knockdown data demonstrated that Hemgn is required for 
Hoxb4 function. 
 
 
Nuclear Localization and Coiled-coil Domain 
 
Hemgn contains a predicted nuclear localization signal (NLS) at N-terminal 
amino acids 61-78 [67]. However, there are no experimental data to confirm the validity 
of this sequence. We generated a Hemgn mutant with truncation of this predicted NLS 
(NLS) to test its function. The mutant was generated by PCR, cloned into a 
MSCV-IRES-GFP retroviral vector, and sequenced completely (Figure 4-9A). The 
mutant was then packaged into a retroviral vector to transduce the murine pro-B cell line 
Ba/F3. Transduced Ba/F3 cells were sorted and expanded in culture. Western blotting of 
Hemgn in the cytoplasmic and nuclear fractions of Ba/F3 cells clearly showed that 
mutant Hemgn was located in the cytoplasm instead of the nucleus (Figure 4-9B, C). 
Thus the predicted NLS is required for the nuclear translocation of Hemgn. 
 
There is little information on the overall structure of Hemgn. Hemgn has no 
identifiable family member in the mouse genome based on the predicted protein domains. 
There is only 1 predicted coiled-coil domain at the N-terminal amino acids 34-50 [67]. 
Part of this sequence is conserved among human, mouse and rat models. The coiled-coil 
motif is often associated with oligomerization or other types of protein-protein interaction 
[71]. Whether the functional NLS and the predicted coiled-coil have any physiological 
significance is not clear. To determine whether the 2 motifs are required for Hemgn 
function, a Hemgn mutant with deletion of the predicted coiled-coil sequence (CC) was 
generated together with the NLS mutant (Figure 4-9A). 
 
A previous study has shown that human EDAG can protect Ba/F3 cells from IL-3 
deprivation induced apoptosis [85]. Therefore, the 2 mutants were tested in this system, 
assuming that Hemgn may exert its function as EDAG does. Stably transduced Ba/F3  
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Figure 4-9. Hemgn mutagenesis 
 
(A) Concensus sequence of the predicted coilded-coil domain (amino acids 34-50) and 
NLS (amino acids 61-78) among human, rat, and mouse Hemgn, and sequences of 2 
mutants. (B) Western blotting on total cell lysate of Ba/F3 cells. (C) The NLS mutant 
(NLS) Hemgn is located in the cytoplasm.  
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cells were sorted and expanded in the presence of IL-3. Before IL-3 withdrawal, dead 
cells were depleted from the culture. After 20 hours of IL-3 withdrawal, apoptosis was 
measured by Annexin V and DAPI staining. As expected, wild-type Hemgn protected 
Ba/F3 cells from IL-3 withdrawal. However the same protective effect was not seen in 
cells transduced with either of the mutant Hemgn retroviral vectors (Figure 4-10). This 
observation indicates that both nuclear translocation and correct protein-protein 
interactions are required for Hemgn function. 
 
In competitive repopulation assay, Hemgn knockout cells showed a mild defect in 
lymphoid reconstitution, but not in myeloid reconstitution (Figure 4-8A). In complement 
to the in vivo study, a myeloid cell line 32D was also used to test the function of Hemgn. 
In contrast to the Ba/F3 cell line, wild-type Hemgn could not protect myeloid 32D cells 
from IL-3 withdrawal induced apoptosis (Figure 4-10), suggesting that the anti-apoptotic 
function might depend on cell context. Hemgn might require the nuclear localization and 
appropriate partners to carry out its function as stated above. However, such co-factors 
might be absent in the myeloid cellular environment. The difference between lymphoid 
and myeloid cells is discussed in Chapter 5. 
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Figure 4-10. IL-3 withdrawal induced apoptosis in Ba/F3 and 32D cells 
 
Ba/F3 and 32D cells were transduced with wild-type and mutant Hemgn respectively. 
Apoptosis was induced in purified transduced cells by IL-3 withdrawal from the culture 
medium for 20 hours. In wild-type Hemgn transduced Ba/F3 cells, the percentage of total 
Annexin V
+
 cells was lower than that of mutant Hemgn (p=4×10-7for CC, p=0.03 for 
NLS, by t-test) or GFP transduced cells (p=0.007). This was not seen in transduced 32D 
cells upon IL-3 withdrawal.  
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CHAPTER 5.    DISCUSSION 
 
 
 This chapter includes discussions on the methodology, results and outlook of this 
study in the context of previous publications. 
 
 
Expression in Erythroblasts 
 
 In this study, we confirmed Hemgn expression in mouse erythroblasts. Findings 
from previous studies on the expression pattern of Hemgn in mouse have been 
contradictory. Ter119
+
 erythrocytes were initially reported to be negative for Hemgn by 
RT-PCR [67]. However, in situ hybridization studies showed Hemgn expression in the 
spleen red pulp, where erythropoiesis occurs actively [67]; a thesis from the same group 
later confirmed that “this gene is expressed in hematopoietic stem/progenitor cells and 
then restricted in erythroid and megakaryocytic lineages” [94].  
 
By studying the developmental stages of erythroid cells with surface markers such 
as CD44, CD71 and Ter119, we confirmed Hemgn expression in erythroid cells and 
megakaryocytes. Further, we found that Hemgn was expressed inTer119
+
 cells in the 
early and mid stages of erythroid cell development, but not in the final stages of 
erythrocyte maturation (Figure 4-3). This result is consistent with published data on the 
in vitro differentiation of mouse and human erythrocytes. In both species, Hemgn/EDAG 
expression is up-regulated during the early stages of differentiation, but is down-
regulated in the final stages [102]. Similar to the expression of mouse Hemgn in erythroid 
cells, the rat homologue RP59 is expressed in erythroblasts and megakaryocytes [74]. It 
is possible previous studies [67, 94] used Ter119
+
 cells from peripheral blood and bone 
marrow respectively that different conclusions were made. Therefore, we conclude that 
Hemgn is expressed by some Ter119
+
 erythroblasts in early and mid stages, but not late 
stages of erythroid development. However, the physiological significance of this 
expression pattern remains unclear. 
 
 
Apoptosis in Heterogeneous Cell Population 
 
 In previous studies, the anti-apoptotic function of Hemgn or EDAG has been 
tested in Ba/F3 cells and primary bone marrow cells [69, 85]. EDAG overexpression can 
protect the cells from IL-3 withdrawal induced apoptosis, probably through NF-B 
activation [85]. The study in Ba/F3 is more straightforward by establishing an EDAG 
overexpressing cell line, in which EDAG expression is relatively homogenous. However, 
in primary bone marrow cells, retroviral vector transduction efficiency cannot reach 
100%, so both transduced and non-transduced cells exist when apoptosis is analyzed [69]. 
 
One concern about such heterogeneous cell culture is, by gating on GFP
+
 cells for 
apoptosis analysis, apoptotic cells that have lost GFP expression are artificially excluded, 
thus the apoptosis is underestimated for GFP
+
 population. During apoptosis, transduced 
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cells lose marker expression soon. A GFP bright cell may become GFP dim but still 
positive, whereas a cell with moderate GFP expression may become totally GFP
-
. In this 
sense, the gating bias is especially significant in a heterogeneous population with low to 
moderate marker expression.  
 
To bypass this bias from gating, prior to the induction of apoptosis, the transduced 
cells were sorted to a highly pure GFP
+
 population that almost every GFP
-
 cell was from 
an originally GFP
+
 one and no cells were excluded on GFP expression for analysis. 
Measurement of apoptosis in a heterogeneous cell population by gating on marker 
expression may not be accurate. 
 
 
Association with Leukemia 
 
 
Human EDAG and Leukemia 
 
 Human EDAG is associated with specific types of leukemia, but the underlying 
evidences are arguable. EDAG is overexpressed in two Bcr-Abl
+
 leukemia cell lines, 
K562 and KU812 [81]. EDAG is also overexpressed in peripheral blood mononuclear 
cells of patients with leukemia, and may be associated with poor prognosis in de novo 
AML patients [84]. EDAG is highly expressed in AML patients having high Erg 
expression (defined by the top 25% percentile), which predicts a poor survival [103]. 
Down-regulation of EDAG expression inhibits the growth of K562 cell and reduces their 
colony forming ability [84]. Molecular studies show that the N-terminal region (amino 
acids 1–124) of EDAG physically interacts with the N-terminus (amino acids 118–187) 
of NPM, a known anti-apoptotic protein, and this interaction enhances the stability of 
NPM, whereas RNAi mediated knockdown of EDAG increases the degradation of NPM 
in K562 cells [86]. Other studies on apoptosis with regard to human EDAG have been 
mostly on murine cells, and therefore their validity is arguable. Because of the relatively 
low homology (46%) between human EDAG and mouse Hemgn, human EDAG may not 
function in the same way as mouse Hemgn. 
 
 The prevalence of EDAG overexpression in specific leukemia types has not been 
studied. A claim that EDAG expression level is higher in leukemia patients than in 
healthy blood donor and complete remission patients [84] may need to be understood in 
more depth. In that study, EDAG expression levels in bone marrow mononuclear cells 
(BMMC) of healthy donor, leukemia patients with and without complete remission are 
compared by RT-PCR, and lower EDAG level is found to be associated with better 
chemotherapy response. However, the BMMC is a heterogeneous population consisting 
of both EDAG expressing leukemic cells and non-expressing cells, and RT-PCR only 
reflects the expression at a population level instead of individual cells. The high 
expression level of EDAG in BMMC can therefore be attributed to a higher percentage of 
leukemic cells in non-remission patients. It is possible that patients with high expression 
level of EDAG in individual leukemic cells responded well to chemotherapy and finally 
reached complete remission, in which case the overall EDAG expression fell to an 
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undetectable level by RT-PCR. EDAG overexpression may not be the reason, but the 
manifestation of poor responses to chemotherapy. Instead, EDAG might be regarded as a 
marker of leukemic cells. 
 
Cytogenetic evidence has been shown to suggest an association of EDAG with 
leukemia [67, 94]. EDAG is located in the 9q22 genomic region, which is a frequent 
leukemia breakpoint. The most frequent cytogenetic lesion involving this region is 
deletion. Among the 408 patients with 9q22 breakpoints whose data were registered at 
the Mitelman Database of Chromosome Aberrations and Gene Fusions in Cancer, 291 
have leukemia (4 inversions, 4 translocations, 10 additions, 273 deletions) [104]. Loss of 
heterozygosity (LOH) is often observed, although the overexpression of EDAG results in 
anti-apoptotic effects in leukemic cells and is observed in leukemia patients [84]. A 
plausible explanation for this seemingly contradictory observation is that the association 
of 9q22 LOH with leukemia incidence is via genes other than EDAG. With the available 
data, it is more reasonable to assume that overexpression, and not loss of function, of 
human EDAG, is associated with oncogenic potency. Data on the association of EDAG 
with leukemia are limited in patients, and the proof of this association in only a single 
cell line makes this conclusion weak. 
 
 Although the above observations are only suggestive of the link between EDAG 
and leukemia, the recent discovery of human EDAG and NPM interaction [86] may 
provide more definitive evidence of the leukemogenesis. NPM is a most frequently 
mutated gene in AML, with the most common NPM mutation being duplication of the 
TCTG sequence at position 956-959 of the coding sequence. This mutation results in the 
loss of the tryptophan residues required for nucleolar localization, and generation of 
novel sequences at the C-terminus. The direct consequence is retention of mutant NPM in 
the cytoplasm, thus sequestrating and degrading ARF in the cytoplasm. Patients with 
AML having this type of NPM mutation show higher sensitivity to chemotherapy but 
also a higher remission rate than those without this mutation [105]. Could EDAG 
overexpression be related to NPM in some AML cases? It is possible that high EDAG 
expression increases the ability of NPM to sequester ARF in the nucleolus and inhibit 
ARF function in the nucleoplasm. This assumption is consistent with the observation that 
overexpression of NPM enhances cell growth and inhibits apoptosis [105]. But whether 
NPM protein increases in EDAG overexpressing primary leukemic cells is not known. 
 
 
Mouse Hemgn and Leukemia Models 
 
The association of mouse Hemgn with leukemia incidence is supported by the 
finding that the mouse chromosome 4B1 region, where Hemgn is located, is involved in 
radiation induced leukemogenesis [106]. However, with the exact mapping of Hemgn 
this rationale has been called into question. The distance between the Hemgn locus and 
the marker D4Mit89 is only approximately 60 kb [107], therefore D4Mit89 can be 
roughly regarded as a marker for the presence or absence of Hemgn. However, of the 14 
radiation induced AML cases, loss of D4Mit89 occurs in 1 case only; of the 21 lympho-
myeloid leukemia (L-ML) cases, loss of D4Mit89 is seen in 9 cases. The 4B1 region is 
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associated with leukemia in this study, but the exact location of this region is across the 
junction of 4A5 and 4B1. When Hemgn was first mapped, its position was estimated to 
be between 4A5 and 4B2, and this is the primary reason to postulate Hemgn might be 
involved in leukemogenesis [66]. As the exact genomic location of Hemgn is now known, 
it is clear that both copies of Hemgn are intact in most radiation induced leukemia cases. 
Therefore, LOH of this gene is less likely to be associated with radiation induced 
leukemia. 
 
From these findings in human and mouse LOH mutations, it is difficult to 
unequivocally conclude that loss of the human EDAG or mouse Hemgn is associated 
with leukemia. On the other hand, there is not sufficient data to conclude that 
overexpression of Hemgn is associated with AML incidence in mouse. Five independent 
AML mouse models [108-111], with known mutations in human leukemia, do not show 
Hemgn overexpression (Table A-7). This challenges the proposed association between 
Hemgn overexpression and leukemia, especially in AML. Considering that EDAG is 
overexpressed in two Bcr-Abl
+
 cell lines and that knockdown of EDAG in K562 cells 
promotes imatinib induced apoptosis [86], could Hemgn be only associated with Bcr-Abl 
leukemia models? To explore this possibility, we analyzed the Gene Expression Omnibus 
database. In 3 independent datasets, though Hemgn expression increased in Bcr-Abl 
transduced Lin
-
 cells (Figure B-3A), there is no evidence that this increase is due to 
Bcr-Abl expression in the LSK population (Figure B-3B, C). In all 3 models, bone 
marrow cells are transduced with control vector or Bcr-Abl vector and transplanted to 
recipients, and microarray analysis is performed on the recipients’ bone marrow cells. 
Considering that the Bcr-Abl
-
 cell line HEL 92.1.7 has high EDAG expression, the 
relationship between Bcr-Abl and EDAG or Hemgn expression appears weak because: 
 
1. The Bcr-Abl mouse models show Hemgn overexpression in Lin- cells only; 
2. The Bcr-Abl mouse models and cell lines do not consistently have 
EDAG/Hemgn overexpression; 
3. EDAG overexpression occurs in both Bcr-Abl positive and negative human 
leukemia cell lines. 
 
Thus, there is no concrete in vivo evidence of the association of mouse Hemgn 
overexpression with any type of leukemia. Why can EDAG be associated with leukemia 
while its mouse homologue Hemgn cannot? The knowledge on EDAG should be 
examined in retrospect. The transgenic mouse model with increased myelopoiesis is 
generated using human EDAG, and all leukemia studies are also conducted with human 
EDAG. With only 46% sequence identity between mouse Hemgn and human EDAG, it is 
not clear to what extent their functioning is similar. The knowledge on human EDAG 
may not necessarily apply to mouse Hemgn. Thus far, there is no mouse Hemgn 
overexpression (transgenic or transplant) model that mimics EDAG overexpression in the 
correct cell context. In this sense, the causal relationship between mouse Hemgn 
overexpression and leukemogenesis is not yet firmly established. To recapitulate the 
scenarios of EDAG overexpression in human, a mouse Hemgn transgenic model with a 
potent promoter both expressed in myeloid and lymphoid lineages needs to be developed. 
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Normal Hematopoiesis and Erythropoiesis 
 
Hematopoietic organs were examined in the Hemgn knockout mouse model based 
on the pattern of Hemgn expression. No gross defects were found in erythrocyte (Figure 
4-5), platelet (Figure 4-6), and HSC (Figure 4-8A) function under steady-state and stress 
conditions. 
 
In some cases, a gene knockout animal model may not present severe or moderate 
phenotype. In the hematopoietic system, there are examples of animal models with mild 
phenotypes that are only seen under specific conditions. The deletions of p21, CD81, 
Prnp and p55 result in decreased peripheral reconstitution only after secondary or tertiary 
transplantation [112]. Similarly, Hif1- might be important for the metabolism of HSCs, 
considering the hypoxic microenvironment of the bone marrow niche, but a Hif1- 
knockout model only shows apparent defect upon secondary transplantation [113]. In 
another glycolysis deficient model, Pdk2 and Pdk4 double knockout mice show a mild 
anemic phenotype. At the progenitor level, the colony forming capacity of the double 
knockout cells are identical to that of control cells, suggesting normal steady-state stem 
cell maintenance [114]. These studies suggest that in some cases, genes may have very 
specific functions, thus if the appropriate aspects of the HSC behavior cannot be 
adequately assayed, gene knockout animal models may not present severe or moderate 
phenotypes. 
 
 The reasons for the apparent lack of phenotype may be complex. Lack of 
phenotype may be attributed to the redundancy of paralogous genes, in which case one or 
more members of the gene family could make up the absent gene. It has been estimated 
that 50% of mouse genes have a related member in the genome [115]. Since Hemgn has 
no identifiable family members in the genome, it is likely that this genetic robustness 
arises from non-paralogous genes or at the network level. The highly specific spatial and 
temporal expression pattern of Hemgn limits its potential to participate in a wide variety 
of protein-protein interactions and transcriptional networks, thereby reducing its 
importance in the network. The only characterized partner of human EDAG thus far is 
NPM [86], and no co-factor of mouse Hemgn has been reported. It has been postulated 
that a protein with many protein-protein interactions is more likely to have an essential 
role [115]. Hemgn might lack a broad protein-protein interaction network that knockout 
of this gene may not produce any detectable abnormalities. 
 
 
Relationship with NPM 
 
 The anti-apoptotic function of human EDAG in K562 cells has been attributed to 
its interaction with NPM [86], a ubiquitously expressed phosphoprotein that is primarily 
found in the nucleolus. As discussed above, EDAG overexpression may be associated 
with leukemia [84], possibly by affecting NPM protein. NPM may be involved in various 
biological processes, such as rRNA synthesis, regulation of chromatin structure and 
transport of rRNA and ribosomal proteins. However, a knockout mouse model suggests 
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that NPM may be dispensable in these biological processes [116]. The anti-apoptotic 
function of NPM is related to p53. It has been postulated that NPM may physically 
interact with p53 and ARF [117, 118]. The tumor suppressor ARF forms a complex with 
MDM2, an E3 ligase of p53 [117]. Because NPM and MDM2 may compete for ARF 
binding [117] and ARF primarily functions in nucleoplasm, when the majority of ARF 
molecules are sequestered by NPM in the  nucleolus, MDM2 is released from 
ARF-MDM2 complex to promote the degradation of p53 (Figure B-2A). 
 
NPM knockout mice are embryonic lethal due to accumulation of DNA damage, 
activation of p53 and increased apoptosis [116, 119]. The apoptosis phenotype can be 
rescued by simultaneous deletion of p53 and NPM, though the embryonic lethality 
remains [119]. The NPM heterozygous animals are viable and fertile [119], but develop a 
hematological syndrome similar to human MDS with mild dysplasia in erythroid and 
megakaryocytic lineages [116]. These models establish the anti-apoptotic role of NPM in 
the context of p53. 
 
On the one hand, siRNA mediated knockdown of EDAG decreases the level of 
NPM in K562 cells and increased the apoptosis induced by imatinib [86], which is a p53 
dependent process [120]. Overexpression of EDAG can enhance the stability of NPM at 
the protein level, possibly by preventing ARF or ubiquitin mediated NPM degradation, 
while not affecting NPM mRNA expression [86]. The physical interaction between the 2 
proteins requires the N-terminal amino acids 1-124 of EDAG and N-terminal amino acids 
118-187 of NPM [86]. The predicted NLS and coiled-coil motif of EDAG both locate in 
the required region. It is not known whether additional domains are also required for their 
physical binding. It is also unclear whether this EDAG-NPM interaction exists in stem 
cells or other cell types and has any physiological significance. As both Hemgn and NPM 
are expressed in mouse HSCs [121, 122], it is possible that this interaction occurs in 
HSCs. Interestingly, in a cohort of cytogenetically normal acute myeloid leukemia 
(CN-AML) patients, EDAG is significantly down-regulated at the RNA level in patients 
with NPM mutations [123], indicating that NPM might regulate the expression of EDAG 
indirectly. NPM is not a transcription factor per se, but can be an essential co-activator of 
transcription factors such as Miz1, NF-B and IRF1 [105]. The NPM mutation also 
increases the transcription rate of RNA polymerase II, which may have a global effect on 
transcription [105]. 
 
 In contrast to NPM, the expression of Hemgn and EDAG is restricted to 
hematopoietic cells, including HSCs. Based on the rationale that EDAG stabilizes NPM 
to protect cells from p53 dependent apoptosis, the role of NPM needs to be specifically 
reviewed in the HSC compartment. To differentiate overexpression models from loss of 
function models, NPM deficiency in HSCs needs to be analyzed. Specifically, in normal 
human lymphoblasts and Fanconi anemia associated AML patient cells, knockdown of 
NPM increases DNA damage induced apoptosis in a p53 dependent manner [124]. 
However, in Hemgn knockout HSCs, we did not observe increased sensitivity to ionizing 
radiation, which is a p53 dependent process (Figure 4-8B). This result leads to the 
questions whether mouse Hemgn is a functional equivalent of human EDAG, and 
whether NPM and Hemgn interact at the protein level across different cell contexts. 
 58 
 
 To answer the two questions, the physical interaction of mouse Hemgn and NPM 
may be tested both in vitro and in vivo. It is possible that mouse Hemgn, though similar 
to human EDAG, does not interact with NPM at all. MEL cell is a mouse 
erythroleukemia cell line with high level of endogenous Hemgn and NPM expression 
[125]. Ba/F3 cell line with Hemgn overexpression is now also established by this study. 
A Co-IP experiment in these two models may be necessary to tell whether Hemgn could 
physically interact with NPM as EDAG does. It is possible the Hemgn-NPM interaction 
might require a third partner, or additional posttranslational modification, such as the 
reported serine 380 phosphorylation of Hemgn [73]. Such phosphorylation may be also 
required for NPM function [126, 127]. It is not known whether these posttranslational 
modifications affect the ability of Hemgn and NPM to physical interact and their 
appropriate functions. The absence of the correct subcellular localization, 
posttranslational modification or the required co-factors may reduce the possibility and 
the significance of the Hemgn-NPM interaction under physiological conditions. 
 
 Further studies may be needed on the in vivo interaction between Hemgn and 
NPM. As it is known that this physical interaction regulates NPM at the posttranslational 
level, a differential expression profile may not reveal any changes in the absence of 
Hemgn. The Hemgn-NPM interaction may be examined by Co-IP in the erythroid cells 
where both proteins are present. If Hemgn-NPM interaction can be confirmed in 
erythroid cells, considering the mild erythroid dysplasia in NPM
+/-
 mice [116], additional 
loss of Hemgn may exacerbate the phenotype in erythrocytes by further reduction of 
NPM protein. 
 
 The anti-apoptotic effect seen in Ba/F3 cells may need further analysis in light of 
NPM and p53. Whether this phenotype could be attributed to a possible Hemgn-NPM 
interaction is not known, but NPM has robust expression in the Ba/F3 cell line [128]. 
Because cytokine deprivation induced apoptosis is generally regarded as being 
independent of p53, in the context of NPM and p53, the protective effect of Hemgn 
overexpression may become more significant when other stresses are applied to induce 
p53-dependent apoptosis. The same assumption could be made to the myeloid 32D cell 
line to explain the lack of protective effect, which may be due to lack of appropriate co-
factors or absence of p53 activation induced by IL-3 withdrawal. In the latter case, with 
stresses to induce p53 activation, a protective effect might be seen in cells overexpressing 
Hemgn. 
 
 
Defect in Lymphoid Cell Reconstitution 
 
 In 2 competitive repopulation assays, bone marrow cells from Hemgn knockout 
animals showed a minor defect in B cell and T cell reconstitution, whereas all other 
lineages, including granulocyte and macrophage had normal reconstitution (Figure 4-8A). 
In the setting of competitive repopulation, all cell extrinsic factors that may affect 
survival, proliferation and differentiation of donor cells have been provided by recipients’ 
cells and competitor cells. Thus the observed defect must be attributed to autonomous 
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factors of donor cells. The absence of a similar phenotype in myeloid lineages implies 
that HSCs develop normally. According to published databases, Hemgn expression is 
lower in CLP [95] and pre-B cell stages [129] than in HSCs. Despite low level of 
expression, Hemgn might be required in lymphoid cell development. This observation 
also reinforces the proposition that Hemgn function may require appropriate cell contexts 
or posttranslational modification. The anti-apoptotic function was also confirmed in 
pro-B Ba/F3 cell, but not in the myeloid 32D cell line (Figure 4-10). 
 
 Based on these preliminary data on lymphoid cell development, the Hemgn 
knockout mouse model could be further analyzed by in vivo and in vitro assays. The 
lymphoid progenitors of the Hemgn knockout model have not been thoroughly examined 
under steady-state conditions. We found that under physiological conditions, the 
knockout animal did not show defect in the number of B cells and T cells (Figure 4-4C). 
However, any subtle defect in CLP or other lymphoid progenitor populations might be 
compensated for later during development by another genetic pathway in the in vivo 
environment such as pathways involving multiple cytokines. Such attenuation in 
phenotypes occurs in the Flt3 knockout model. The reduction of CLP in the Flt3 
knockout animal is almost 10-fold, whereas the mature B cell reduces only slightly and 
the number of pre-T cells is normal [130]. The Hemgn knockout bone marrow cells have 
been tested for the ability to form myeloid colonies, but their ability to form lymphoid 
colonies in vitro still remains unclear. At this point, in vitro colony assay specific for B 
cells and T cells may be necessary. 
 
 The NPM-Hemgn interaction might also provide a mechanism for the observed 
defect in lymphoid reconstitution. NPM is expressed at relatively high level in the CLPs 
[95]. Because NPM is actively involved in multiple biological processes such as 
ribosome biogenesis, centrosome duplication and cell cycle, it is premature to postulate 
that the lymphoid defect in Hemgn knockout cells is due to NPM and p53 related 
apoptosis, as discussed later in light of NF-B signaling. As the NPM RNA level is not 
affected in the absence of EDAG [86], a comparison of NPM protein level in the CLPs or 
other lymphoid cells of Hemgn knockout and wild-type animals by flow cytometry may 
provide valuable information. A decrease in the NPM protein level is expected in Hemgn 
knockout CLPs or lymphoid cells. 
 
 The defect of Hemgn knockout cells to reconstitute lymphoid cells might be 
related to NF-B signaling, a regulator of lymphopoiesis (Figure B-2B). It has not yet 
been fully established whether NF-B signaling has an important function in early 
lymphopoiesis, but upon transplantation it can protect early lymphocytes from tumor 
necrosis factor (TNF) induced cell death [131]. NF-B also plays an important role 
during the later stages of lymphopoiesis, including pre-BCR and pre-TCR signaling, 
positive and negative selection, and maintenance of the lymphocytes [131]. NF-B 
activation occurs in human EDAG overexpressing Ba/F3 cells [85]. Again this 
relationship might be mediated via NPM. The level of NPM may directly affect the 
activity of NF-B [132]. NPM interacts physically with p50 and p65, both members of 
the NF-B family [132]. A mutant NPM with cytoplasmic localization has been 
associated with reduced NF-B activity in AML patients [133]. All these evidences 
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suggest that lack of Hemgn may decrease NF-B activity through reduced NPM stability, 
and reduction of NF-B activity specifically affects lymphopoiesis. However, if this is 
true, a competitive repopulation setting may no longer be the best assay to test the role of 
Hemgn and NF-B in early lymphopoiesis. When p50 and p65 double knockout fetal 
liver cells are transplanted, TNF production is associated with increased granulopoiesis, 
and kills the lymphoid progenitors [131, 134]. However a co-transfer of the wild-type 
cells with NF-B knockout fetal liver may reduce the TNF produced by excessive 
granulopoiesis, thus attenuating the proposed phenotype [134]. This might also explain 
why only a mild reduction in lymphopoiesis was seen in this study. The normal 
reconstitution of the myeloid cells in these recipient animals would not produce the 
excessive TNF that is necessary to initiate lymphoid cell death. For the same reason, as 
no endogenous TNF signal is present under steady-state conditions, the lymphopoiesis of 
Hemgn knockout animal is also normal. 
 
 
Differences between Myeloid and Lymphoid Cells 
 
In the primary cells, Hemgn knockout bone marrow cells showed reconstitution 
defect only in lymphoid lineages but not in myeloid lineages (Figure 4-8A), whereas in 
cell lines, Hemgn overexpression only showed protection on Ba/F3 cells but not 32D 
cells (Figure 4-10). Similarly, this discrepancy between lymphoid and myeloid cells is 
also seen for human EDAG. EDAG overexpression in Ba/F3 cells increases NF-B 
signaling [85] while EDAG knockdown does not lead to reduced NF-B activity in K562 
cells [84].These different phenotypes between lymphoid and myeloid cells may be 
attributed to 2 possibilities. The first explanation is Hemgn may interact with specific co-
factors only in lymphoid cells. This depends on whether such co-factors are expressed 
with the required posttranslational modification in the specific cell types. However, even 
if Hemgn interacts with a common set of co-factors and regulates the same signaling 
pathway in both lymphoid and myeloid cells, their responses can still be very different. 
For example, lymphoid and myeloid cells show different dependence of NF-B signaling 
for survival. While no NF-B activity can be detected in the resting monocytes, it may be 
correlated to the activation process [135]. Inhibition of NF-B can be associated with 
increased apoptosis of granulocytes only under inflammatory or stress conditions [135]. 
On the contrary, the functions of NF-B in the lymphoid cells are better established by 
knockout mouse model. In animals transplanted with the p50 and p65 double knockout 
cells, the myelopoiesis increases relatively whereas lymphopoiesis is impaired [134]. 
However, it is not clear whether lymphoid and myeloid cell lines have different 
dependence on NF-B signaling, as shown in the knockout mouse model. 
 
 
Relationship with Hoxb4 
 
 Hemgn is characterized as a direct target gene during Hoxb4 mediated ex vivo 
HSC expansion [69]. Hemgn knockdown significantly impairs the Hoxb4 function, but 
does not totally ablate Hoxb4 mediated HSC expansion [69], indicating that other 
mechanisms also control Hoxb4 function. Similarly, complete knockout of Hemgn 
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caused an approximately 50% reduction in secondary colony numbers when transduced 
with Hoxb4 (Figure B-1). This loss of function study in combination with previous in 
vitro data demonstrated that Hemgn is a direct target of Hoxb4 and is required for Hoxb4 
mediated HSC expansion. It is also possible this HSC expansion is mediated by the 
Hemgn-NPM interaction. Hoxb4 does not regulate NPM expression per se, as seen by the 
expression profile of Hoxb4 overexpressing bone marrow cells [69]. 
 
 The defect in lymphoid reconstitution might be contradictory to what is known in 
a Hoxb4 overexpressing mouse model. Hoxb4 overexpression leads to increased Hemgn 
level [69] and decreased lymphoid reconstitution upon transplantation [87]. Following 
this rationale, Hemgn overexpression, instead of knockout, should be related with defect 
of lymphoid cells. The human EDAG transgenic mouse model show inhibition of 
lymphopoiesis [77]. However, the Hemgn knockout bone marrow cells showed defect in 
lymphoid reconstitution too (Figure 4-8A). Similar phenotypes are observed in mouse 
models with totally opposite Hemgn expression status. This can be explained by the 
difference between gain of function model and loss of function model. Hoxb4 is a master 
gene in hematopoiesis, whose overexpression initiates a series of changes in the 
expression profile, among which elevated Hemgn expression is only one. The decreased 
lymphopoiesis seen in the Hoxb4 overexpression model may not necessarily be 
physiological, or be attributed to increased Hemgn level. In the overexpression model, 
excessive Hoxb4 may bind to the promoters or enhancers of its non-physiological targets 
and regulate transcription. Also, Hoxb4 can directly bind to promoters of lymphoid genes 
such as B220 [136]. It is also possible that Hoxb4 regulates key lymphoid genes that have 
greater functions than NPM or NF-B. On the other hand, the phenotypes seen in gene 
knockout model are closer to physiological scenarios, as it is loss of function right in the 
cells with endogenous Hemgn expression.  
 
 
Potential Use of Hemgn Knockout and Mutants to Characterize Co-factors 
 
 As discussed above, to elucidate the anti-apoptotic function of Hemgn, it may be 
necessary to characterize its binding partners in cell lines and primary cells. NPM might 
be a candidate, but not exclusively. To answer whether such binding partners exist, cell 
lysate may be extracted from primary bone marrow cells or Ba/F3 cells, and analyzed by 
non-reducing and non-denaturing Western blot. If such co-factors of Hemgn do exist, it is 
possible Hemgn shows higher molecular weight in the non-reducing and non-denaturing 
gel than its size in the reducing and denaturing environment. However, if majority of 
Hemgn molecules are in the free form, or its binding partners are too small, it may be 
difficult to detect any change in the apparent molecular weight in migration. 
 
A pull-down assay with Hemgn antibody in appropriate cell type followed by 
mass spectrum analysis may be a viable method to indentify its binding partners, similar 
to the characterization of NPM as a binding partner of human EDAG [86]. In pull-down 
assays, to minimize the background from IgG heavy chain and light chain, Hemgn 
antibody should be conjugated to the immobilized beads covalently. Although the 
available Hemgn antibody is competent to perform the immunoprecipitation, its 
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polyclonal nature will inevitably result in significant non-specific binding in the assay. 
To eliminate the false positive candidates, the cells from Hemgn knockout animals can be 
used as negative control for primary cells, including erythroblasts and other progenitor 
cells. In the Ba/F3 cell line, the presence of low level of endogenous Hemgn may prevent 
the usage of wild-type Ba/F3 as a perfect negative control. In this case, the NLS or 
coiled-coil motif mutant transduced Ba/F3 cells can be used as negative controls. The 
loss of NLS or coiled-coil motif possibly ablates the physical interaction between Hemgn 
and its partners, and any proteins pulled down by these two mutants might be non-
specific partners. 
 
 
Clinical Relevance 
 
 The finding that knockdown of EDAG in K562 cells leads to increased imatinib 
induced apoptosis [86], and decreased ability of colony formation and cell growth [137], 
suggests a potential application of EDAG inhibitors in combination with imatinib in some 
patients with myeloid or erythroid leukemia. The EDAG-NPM interaction also provides 
grounds for a potential therapy in AML patients carrying the NPM mutation. 
 
Clinical resistance to imatinib is common in patients with acute leukemia, and 
occurs within 3-6 months of treatment in more than 70% of patients [138]. Imatinib 
resistance develops via selection of leukemic cells with mutant Bcr-Abl or by Mdr 
overexpression. Once resistance develops, the disease progresses rapidly and is 
aggressive in most patients. Besides drugs that directly target the Bcr-Abl variants or 
Mdr, agents that enhance apoptosis selectively in leukemic cells have been tested in 
combination with imatinib in cell cultures with the aim of finding an additive or 
synergistic effect, and results have been encouraging. Such drugs include As2O3, 
flavopiridol (cyclin-dependent kinase inhibitor), suberoylanilide hydroxamic acid 
(histone deacetylase inhibitor), and TNF related apoptosis-inducing ligands [139]. 
Ideally, candidate drugs should be effective, have few side effects or systemic toxicity, 
and be selective for leukemic cells. Whether a potential EDAG inhibitor can be candidate 
drug remains an open question. 
 
A possible inverse relationship has been reported between the expression level of 
EDAG and response to chemotherapy [84], possibly through activation of NF-B 
signaling [85], though the exact chemotherapy reagents used in the study is not specified. 
Before such small molecule inhibitors are developed, the safety of targeting EDAG needs 
to be examined. By ablation of EDAG’s homologous gene Hemgn in mouse genome, this 
study demonstrated that there was no gross defect or hematopoietic abnormality in the 
mouse model. This implies that EDAG might not play an important role in normal human 
hematopoiesis, and might be safe to target in leukemic cells because of its highly 
restricted expression pattern. EDAG is pathologically up-regulated in leukemic cells [84]. 
If inhibition of EDAG function causes no defects in HSCs, RBCs and sperm development 
in humans, as seen for mouse Hemgn, but enhances the efficacy of imatinib as seen in 
K562 cells, the safety and efficacy of such inhibitor can be further examined. 
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A Proposed Model for Hemgn Function 
 
 As discussed above, it is possible Hemgn may interact with specific co-factors 
through a coiled-coil motif in the lymphoid cell context and possibly in certain leukemic 
cells, thus may protect the cells from apoptosis induced by specific signaling. The 
proposed protein-protein interaction might require its correct subcellular localization in 
the nucleus, and correct posttranslational modifications such as the S380 phosphorylation 
[73]. The anti-apoptotic protein NPM could be a candidate co-factor of Hemgn. In the 
proposed model, by stabilizing NPM from degradation, Hemgn indirectly inhibits p53 
activity (Figure B-2A) and/or increases the pro-survival NF-B activity (Figure B-2B), 
as the human EDAG does [85, 86]. As NF-B signaling has been proposed to participate 
in early lymphopoiesis by regulating TNF induced apoptosis [131], the mild lymphoid 
defect in Hemgn knockout cells upon transplantation might be related to decreased 
NF-B activity, and needs to be further explored. 
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APPENDIX A.  SUPPLEMENTARY TABLES 
 
 
Table A-1. Estimated HSC frequency in mouse bone marrow 
 
 
Sources: Ema, H., et al., Quantification of self-renewal capacity in single hematopoietic 
stem cells from nrmal and Lnk-deficient mice. Developmental Cell, 2005. 8(6): p. 907-
914. Kiel, M.J., et al., SLAM Family Receptors Distinguish Hematopoietic Stem and 
Progenitor Cells and Reveal Endothelial Niches for Stem Cells. Cell, 2005. 121(7): p. 
1109-1121.  
 
Surface markers Frequency in BM Single cell reconstitution 
CD150
+
CD48
−
Sca-1
+
Lin
−
c-Kit
+
 5.8±1.2×10-5 47±7% [9] 
CD150
+
CD48
−
CD41− 6.5±0.9×10-5 45% [9] 
CD150
+
CD48− 8.4±2.8×10-5 21% [9] 
CD34
-
 Sca-1
+
Lin
−
c-Kit
+
 5×10-5 25% [140] 
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Table A-2. PCR conditions and cloning strategies for targeting construct 
 
Description Primers 
(Table A-3) 
Annealing 
(C) 
Extension time 
(minute:second) 
Size 
(bp) 
Digestion 
enzymes 
Vector 
5’ BAC retrieving arm Gp001, Gp002 56 1:30 1049 BamHI, PstI VP101 
3’ BAC retrieving arm Gp003, Gp004 56 1:30 1050 PstI, NotI VP101 
loxP-neo-loxP 5' mini arm Gp009, Gp010 56 0:30 329 KpnI, EcoRI PL452 
loxP-neo-loxP 3' mini arm Gp011, Gp012 56 0:30 425 BamHI, NotI PL452 
FRT-neo-FRT-loxP 5' mini arm Gp013, Gp014 56 0:30 296 KpnI, EcoRI PL451 
FRT-neo-FRT-loxP 3' mini arm Gp015, Gp016 56 0:30 305 BamHI, NotI PL451 
Single loxP ESC screen Gp079, Gp083 58 6:00 5668   
FRT-neo-FRT-loxP ESC screen Gp088, Gp091 58 8:00 7557   
5’ Southern probe Gp005, Gp006 56 0:45 528   
3’ Southern probe Gp007, Gp008 56 0:45 610   
 
  
 77 
Table A-3. Primer sets for targeting constructs and ES cell screening 
 
Name Description Strand Sequence (restriction enzyme sites underlined) 
Gp001 BAC 5' retrieving-arm sense CGCGGATCCTTGAACTATCACCCAACTA 
Gp002 BAC 5' retrieving-arm antisense AACTGCAGCTCTGCCCTCTACCTCT 
Gp003 BAC 3' retrieving-arm sense AACTGCAGGAGTATCGGCTCCGGCA 
Gp004 BAC 3' retrieving-arm antisense AAGGAAAAAAGCGGCCGCGCTTCCAGGAGCTGCAAT 
Gp005 5' southern sense GTGGCACTGTAACTCACAGCAG 
Gp006 5' southern antisense CCAAGGCCATTCTCTGTG 
Gp007 3' southern sense TGTTTTCTTACCTCTTGGACCC 
Gp008 3' southern antisense CACAGCTGTGATCCCATAAATG 
Gp009 loxP-neo-loxP 5' mini arm sense GGGGTACCAAAATGCCTGCTCCAGC 
Gp010 loxP-neo-loxP 5' mini arm antisense CGGAATTCACTAGTTATGTAGCCTGGGTCTGGA 
Gp011 loxP-neo-loxP 3' mini arm sense CGCGGATCCCTGAGACTCCTATTTC 
Gp012 loxP-neo-loxP 3' mini arm antisense AAGGAAAAAAGCGGCCGCTCACCACAGAATCTTGT 
Gp013 FRT-neo-FRT-loxP 5' mini arm sense GGGGTACCTCTTAGTTTATGCGGGGATG 
Gp014 FRT-neo-FRT-loxP 5' mini arm antisense CGGAATTCCAACCACATGGTGGCT 
Gp015 FRT-neo-FRT-loxP 3' mini arm sense CGCGGATCCGCTAGCCTGGGATTTGAACTCG 
Gp016 FRT-neo-FRT-loxP 3' mini arm antisense AAGGAAAAAAGCGGCCGCACACTGTTTCCTTGGG 
Gp041 Exon2 sequencing sense ACCCAGGCATACACTGGCAC 
Gp042 Exon3 sequencing sense CACATGCAGGCAAAAACACC 
Gp043 Exon4 sequencing sense TAAGGCCATGTAACAAGGCC 
Gp044 Exon4 sequencing sense AGACAGCTGTGCCCCAAACC 
Gp045 Exon4 sequencing sense GAAGCAGTTGAACCTGAATT 
Gp046 Exon5 sequencing sense GACAGTGCCAACGTTGTTTA 
Gp047 Exon5 sequencing sense GTAGTTCTGAGGAGAAGATAGC 
Gp079 Single loxP ESC screening antisense GGTTATTGAATATGATCGGAATT 
Gp083 Single loxP ESC screening sense AGGGTCAGACATTCCAAACTCAA 
Gp088 3’ loxP ESC screening sense GCTCAGGAGGGTTTACTTAC 
Gp091 3’ loxP ESC screening antisense AGACAGAGGCAGGCAGATCC 
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Table A-4. Primers for mutagenesis and sequencing 
 
Name Description Sequence 
Gp113 34-50 sense ATCATTGGATCTTGGAGTCAGACATCACAATGGCTC 
Gp114 34-50 antisense GAGCCATTGTGATGTCTGACTCCAAGATCCAATGAT 
Gp115 61-78 sense TGGCTCCTTGGAGAACAGCAAGGGAACGTGGAGCAA 
Gp116 61-78 antisense TTGCTCCACGTTCCCTTGCTGTTCTCCAAGGAGCCA 
Gp117 MSCV backbone ACTAGTTAGCTAACTAGCTC 
Gp118 IRES backbone CACAACGTGGCACTGGGGTT 
Gp119 Sequencing TAGGCTGCTTGTGAAGTC 
Gp120 Sequencing TGCCAGGAAACAACTGTGTC 
Gp121 Sequencing GAGCCTAAACACAGCCTTCC 
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Table A-5. PCR parameters for mutagenesis 
 
Name Primers Annealing 
(°C) 
Extension 
(minute:second) 
Template 
34 Gp117, Gp114 56 1:00 MSCV-Hemgn-iGFP 
50 Gp113, Gp118 56 1:00 MSCV-Hemgn-iGFP 
61 Gp117, Gp116 56 1:00 MSCV-Hemgn-iGFP 
78 Gp115, Gp118 56 1:00 MSCV-Hemgn-iGFP 
CC Gp117, Gp118 56 1:30 34+50 
NLS Gp117, Gp118 56 1:30 61+78 
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Table A-6. Leukemia mouse models do not show Hemgn overexpression 
 
Leukemia model Disease condition Leukemia cell 
MLL-AF9 AML Lin
–
Sca-1
–
c-Kit
high
 FcRγ+CD34+ [109] 
HoxA9/Meis1 AML Lin
–
Sca-1
–
c-Kit
high
 FcRγ+CD34+ [109] 
Gata-1 delta N M7 AML Megakaryocytes [110] 
Cebpa AML Mac1
+
, c-Kit
+
 myeloid progenitor [111] 
SALL4B leukemia, MDS-like N/A [108] 
 
Sources: Li, Z., et al., Developmental stage–selective effect of somatically mutated 
leukemogenic transcription factor GATA1. Nature Genetics, 2005. 37(6): p. 613-619. Ma, 
Y., et al., SALL4, a novel oncogene, is constitutively expressed in human acute myeloid 
leukemia (AML) and induces AML in transgenic mice. Blood, 2006. 108(8): p. 2726. 
Kirstetter, P., et al., Modeling of C/EBPa mutant acute myeloid leukemia reveals a 
common expression signature of committed myeloid leukemia-initiating cells. Cancer 
Cell, 2008. 13(4): p. 299-310. Wang, Y., et al., The Wnt/b-Catenin pathway is required 
for the cevelopment of leukemia stem cells in AML. Science, 2010. 327(5973): p. 1650-
1653. 
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APPENDIX B.  SUPPLEMENTARY FIGURES 
 
 
 
 
 
Figure B-1. Impairment of Hoxb4 function in Hemgn knockout bone marrow cells 
 
Both wild-type and Hemgn knockout bone marrow cells were transduced with 
MSCV-Hoxb4-IRES-GFP retroviral vector. The transduced cells were cultured in M3434 
medium for the growth of primary colonies. Primary colonies were collected 7 days later. 
The cells were pooled and replated for the growth of secondary colonies. The colony 
numbers were counted 7 days later. This experiment was carried out only once by Hui Yu 
in Brian Sorrentino lab. 
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Figure B-2.  Hemgn and NPM in relation to p53 and NF-B 
 
(A) Hemgn might interact with NPM to affect p53 activity through ARF and MDM2. (B) 
Hemgn might regulate NF-B signaling though its interaction with NPM. NF-B may be 
required for early lymphopoiesis. 
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Figure B-3.  Hemgn expression is not associated with Bcr-Abl 
 
Hemgn expression levels of 3 independent Bcr-Abl leukemia mouse models are 
compared with data from Gene Expression Omnibus database. All 3 models transplanted 
Bcr-Abl transduced bone marrow cells to recipients and analyzed the bone marrow Lin
-
 
or LSK population as indicated here by differential gene expression array after 
reconstitution. (A) GSE37907; (B) GSE10912; (C) GSE36096. 
 
Sources: GSE37907, GSE10912 and GSE36096 of Gene Expression Omnibus repository. 
Available from: www.ncbi.nlm.nih.gov/gds. 
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